```
=> e pato janos/au
E1            1      PATO J S/AU
E2            1      PATO JAMES L KENNEDY CARLOS N/AU
E3           49 --> PATO JANOS/AU
E4            1      PATO JOSE M/AU
E5            1      PATO JOSE MARCIO MARTINS/AU
E6            1      PATO JOSE MARCIO SALGADO/AU
E7            1      PATO KA FR/AU
E8            2      PATO L/AU
E9            1      PATO L M/AU
E10           5      PATO LIVIA/AU
E11           3      PATO LIVIA G/AU
E12          49      PATO M/AU

=> s e3 and mycobact?
L1            4 "PATO JANOS"/AU AND MYCOBACT?

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2            4 DUP REM L1 (0 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y


L2   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2005:238994  CAPLUS
DN   142:316820
TI   Preparation of hetero-bicyclic fused thieno-pyran compounds as
     antibacterial, antiviral, antitumor, and pharmaceutically active agents
IN   Koul, Anil; Klebl, Bert; Mueller, Gerhard; Missio, Andrea; Schwab,
     Wilfried; Hafenbradl, Doris; Neumann, Lars; Sommer, Marc-Nicola; Mueller,
     Stefan; Hoppe, Edmund; Freisleben, Achim; Backes, Alexander; Hartung,
     Christian; Felber, Beatrice; Zech, Birgit; Engkvist, Ola; Keri, Gyoergy;
     Oerfi, Laszlo; Banhegyi, Peter; Greff, Zoltan; Horvath, Zoltan; Varga,
     Zoltan; Marko, Peter; Pato, Janos; Szabadkai, Istvan;
     Szekelyhidi, Zsolt; Waczek, Frigyes
PA   Axxima Pharmaceuticals A.-G., Germany
SO   PCT Int. Appl., 259 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    -------------------      --------
PI   WO 2005023818         A2    20050317    WO 2004-EP10161          20040910
     WO 2005023818         A3    20050825
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     AU 2004270394         A1    20050317    AU 2004-270394           20040910
     CA 2572750            A1    20050317    CA 2004-2572750          20040910
     EP 1670804            A2    20060621    EP 2004-786934           20040910
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
PRAI EP 2003-20616         A     20030910
```

	US 2003-502606P	P	20030915
	EP 2004-4891	A	20040302
	US 2004-551341P	P	20040310
	EP 2004-12814	A	20040528
	US 2004-577043P	P	20040607
	WO 2004-EP10161	W	20040910

OS MARPAT 142:316820

AB Described are hetero-bicyclic compds. such as 4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]thiopyran-3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid amides, or benzo[b]thiophene-3-carboxylic acid amides I, wherein X1 is S, O, NH, substituted nitrogen; Y1-Y4 form with the ring containing X1 a hetero-bicyclic ring system; R1 is H, alkyl, cycloalkyl, heterocycle, alkynyl, substituted Ph, acyl, benzyl; R2 is amide, thioamide, sulfonamide, ester, sulfonyl; R3 is H, acyl, thio-ketone, sulfonyl, amide, thio-amide, diketone-amide, ester, thio-ester; and pharmaceutically acceptable salts thereof, the use of these derivs. for the prophylaxis and/or treatment of various diseases such as infectious diseases, including mycobacteria-induced infections and opportunistic diseases, prion diseases, immunol. diseases, autoimmune diseases, bipolar and clin. disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, as well as compns. containing at least one hetero-bicyclic compound and/or pharmaceutically acceptable salts thereof. Furthermore, reaction procedures for the synthesis of the hetero-bicyclic compound are disclosed. Thus, benzo[b]thiophen-carboxylic acid amide II was prepared and tested in vitro for its inhibitory effect on mycobacterial protein kinase G (IC50 = 0.1-1.0 μM).

L2 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:722914 CAPLUS

DN 141:236625

TI Inhibitors of mycobacterial serine/threonine protein kinases for the treatment of mycobacterial infections

IN Pato, Janos; Keri, Gyorgy; Orfi, Laszlo; Waczek, Frigyes; Horvath, Zoltan; Banhegyi, Peter; Szabadkai, Istavan; Marosfalvi, Jeno; Hegymegi-Barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas, Axel; Bacher, Gerald; Missio, Andrea; Koul, Anil

PA Hung.

SO U.S. Pat. Appl. Publ., 51 pp., Cont.-in-part of Appl. No. PCT/EP03/03697. CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004171603	A1	20040902	US 2003-715591	20031118
WO 2002094796	A2	20021128	WO 2002-EP5573	20020521
WO 2002094796	A3	20031204		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2003084947	A1	20031016	WO 2003-EP3697	20030409

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI EP 2001-112289 A 20010518
US 2001-292325P P 20010522
US 2001-298902P P 20010619
EP 2001-115508 A 20010627
EP 2002-7923 A 20020409
WO 2002-EP5573 A2 20020521
WO 2003-EP3697 A2 20030409

OS MARPAT 141:236625

AB Mycobacterial serine/threonine protein kinases, particularly protein kinase G (PknG), are effective therapeutic targets for the treatment of mycobacterial infections. The invention discloses the use of mycobacterial serine/threonine protein kinases for developing methods for detection and determination of these kinases for recognizing and monitoring diseases and for controlling therapy of diseases. Addnl. disclosed are 4,5,6,7-tetrahydrobenzo[b]thiophene compds., benzo[g]quinoxaline compds., and pharmaceutically acceptable salts thereof, and methods of using such compds. and salts thereof for the prophylaxis and/or treatment of virally and/or bacterially induced infections, particularly mycobacteria-induced infections, including opportunistic infections, as well as pharmaceutical compns. containing at least one 4,5,6,7-tetrahydrobenzo[b]thiophene compound and/or benzo[g]quinoxaline compound and/or pharmaceutically acceptable salts thereof in a pharmaceutically acceptable carrier.

L2 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:906175 CAPLUS
DN 138:14074
TI Preparation of benzo[g]quinoxalines for use against infectious diseases
IN Pato, Janos; Keri, Gyoergy; Oerfi, Laszlo; Waczek, Frigyes; Horvath, Zoltan; Banhegyi, Peter; Szabadkai, Istvan; Marosfalvi, Jenoe; Hegymegi-barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas, Axel; Bacher, Gerald; Daub, Henrik; Obert, Sabine; Kurtenbach, Alexander; Habenberger, Peter
PA Axxima Pharmaceuticals Ag, Germany; et al.
SO PCT Int. Appl., 237 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002094796	A2	20021128	WO 2002-EP5573	20020521
	WO 2002094796	A3	20031204		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	AU 2002312927	A1	20021203	AU 2002-312927	20020521
	US 2004171603	A1	20040902	US 2003-715591	20031118
PRAI	EP 2001-112289	A	20010518		

US 2001-292325P	P	20010522
US 2001-298902P	P	20010619
EP 2001-115508	A	20010627
EP 2002-7923	A	20020409
WO 2002-EP5573	W	20020521
WO 2003-EP3697	A2	20030409

OS MARPAT 138:14074

AB The present invention relates to benzo[g]quinoxaline derivs. (shown as I; e.g. 2,3-bis(2-thienyl)benzo[g]quinoxaline and benzo[g]quinoxalin-2-yl(3-bromophenyl)amine), processes for manufacturing said benzo[g]quinoxaline derivs., the use of the benzo[g]quinoxaline derivs. as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases and opportunistic infections, diabetes, cancer, inflammation, as well as compns. containing at least one benzo[g]quinoxaline derivative and/or pharmaceutically acceptable salt thereof. Further, the present invention is directed to methods for preventing and/or treating of infectious diseases, diabetes, cancer, and inflammation using the inventive benzo[g]quinoxaline derivs. The inventive benzo[g]quinoxaline derivs. exert their antiproliferative effect on M. bovis BCG and M. tuberculosis Erdmann at concns. between <<1 μM and 32 μM. In contrast, growth of E. coli XI-1 blue was not affected by benzo[g]quinoxaline derivs. at concns. >10 μM. The benzo[g]quinoxaline compds. are able to inhibit HI virus replication up to 63% after 6 days at a concentration of 1 μM. 5,10-Dibromo-2-(thiophen-3-yl)-3-(thiophen-2-yl)benzo[g]quinoxaline is able to decrease the activity of the herpes viral target UL-97 by 75%. Results for inhibition of HCMV target RICK for 5 I, of influenza replication for 7 I, of hepatitis B virus for 5 I, of TNFα signaling for 11 I, of human cellular protein kinases (Akt, Abl, PDGFR, Src) for 7 I, of A549 and Jurkat cells for 18 I, of human cellular protein kinase Akt known as a target for diabetes for 4 I, and of human protein kinases SRPK1 and SRPK2 (indicative of hepatitis B virus replication inhibition) for 8 and 1 I, resp., are tabulated. Results for activation of the insulin receptor InsR by 3 I, effect of 2 I on viability of Huh-5-2 replicon cells by the Alamar Blue toxicity assay, effect of 2 I on autonomous replication of hepatitis C virus replicons in the Huh-5-2 cell line by luciferase reporter assay, are tabulated. In I: R1 and R2 = -(CH2)p-NH-(CH2)n-R9, -(CH2)s-S-(CH2)m-R10, -(CH2)m-O-(CH2)p-R11, -(CH2)r-R3, -CH:CH-R11, -(CH2)m-CH(OH)(CH2)p-R11, -(CH2)q-R11, -R9, R10, -R12, -R13, etc. R3, R4, R5, R6, R7, and R8 = -H, -F, -Cl, -Br, -I, -SO3H, -SO3NH2, -(CH2)s-COOR16, -(CH2)p-COOR17, -OR16, -SR16, -NR16R17, -OOCR16, -OOCR17, -NH-CO-R16, -NH-CO-R17, -CO-NH-R16, -CO-NH-R17, -NO2, -N3, -CN, -OCN, -NCO, -SCN, -NCS, CO-R16, CO-R17, -COCN, -CONR16R17, -SOR16, -SO2R16, -SO2R17, -SO3R16, -SO3R17, OCF3. R9, R10, and R11 = -CN, NR16R17, -NHR16, NHR17, etc. R12, R13, R14, and R15 = R3, R4, R5, R6, R16, R17, CH(CO2R16)(CO2R17), CH(CN)(CO2R16), CH(CN)C(O)NHAr (Ar = R14- and R15-substituted phenyl); R16 and R17 = -H, -CH3, -C2H5, -Pr, -CHMe2, -Bu, -C5H11, -C6H13, -cyclo-C6H11, -cyclo-C5H9, -cyclo-C4H7, -cyclo-C3H5, -(CH2)r-CHMe2, -CHMeEt, -CMe3, -CH:CH2, -CH2-CH:CH2, Ph, --CH2Ph, -C2H4Ph, -CH(CN)2, -CF3, -CCl3, -CBr3, -C2F5, -(CH2)r-OH, -CH2F, -CH2Cl, -CH2Br, -CH2I, -CHF2, -CHCl2, -CHBr2, -(CH2)r-SH, -C6H4-CH3, -C6H3Me2, pyridyl, 2-pyrimidinyl, etc. M = 0-6, n = 0-6, p = 0-6, q = 0-6, r = 1-6, s = 0-6. Also claimed are the corresponding N-oxides in position 1 and/or 4 of these compds., the corresponding reduced forms of these compds. wherein the double bond in position 1 and/or 3 is hydrogenated, and pharmaceutically acceptable salts of I. About 42 example prepns. and 406 compds. with characterization data are included. 1H-benzo[g]quinoxaline-2-one was prepared in 90% yield by dissolving 20 mmol 2,3-diaminonaphthalene in a mixture of 5 mL DMF and 50 mL EtOH and adding 5 mL aqueous solution (50%) of glyoxalic acid and the mixture was stirred for 2 h at reflux temperature The reaction mixture was cooled to room temperature and the product was filtered, washed two times with Et2O and dried.

L2 ANSWER 4 OF 4 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

AN 1993:362988 BIOSIS
DN PREV199396048663
TI Preparation of egg albumin microparticles for oral application.
AU Mora, Melinda [Reprint author]; Pato, Janos
CS Central Res. Inst. Chem., Hung. Acad. Sci., P.O. Box 17, 1526 Budapest, Hungary
SO Journal of Controlled Release, (1993) Vol. 25, No. 1-2, pp. 107-113. CODEN: JCREEC. ISSN: 0168-3659.
DT Article
LA English
ED Entered STN: 6 Aug 1993
Last Updated on STN: 8 Aug 1993
AB Gentamicin sulfate, a mixture of aminoglycoside type antibiotics applied in veterinary practice, was entrapped in a protein cover in order to prevent its decomposition before absorption from the gastrointestinal system. Unpurified egg albumin was used for this purpose. For detection of the drug a fluorescence labeled was introduced. The microparticles were prepared by a heat stabilization method in a water/oil system. The drug-release was checked in in vitro experiments. Since the drug retaining ability of the microspheres was not satisfactory after this procedure, further hardening was accomplished by chemical crosslinks which were induced with glutaraldehyde. We have examined the effect of changes in different parameters of the synthesis of the drug-retaining ability of produced microcapsules. We have produced microspheres which hold about 80% of entrapped material even after 4 h at pH 7,2, which corresponds to the conditions in saliva and rumen of animals but having reached the stomach they presumably release the total amount of the drug.

```
=> e keri gyorgy/au
E1            1     KERI GYOGY/AU
E2            3     KERI GYORGI/AU
E3          249 --> KERI GYORGY/AU
E4            3     KERI H/AU
E5            1     KERI HELMUT/AU
E6            1     KERI HIDEAKI/AU
E7           13     KERI I/AU
E8            1     KERI IMRE/AU
E9           11     KERI J/AU
E10          16     KERI J E/AU
E11           1     KERI JANOS/AU
E12           4     KERI JONETTE E/AU

=> s e2-e3 and mycobacter?
L3            1 ("KERI GYORGI"/AU OR "KERI GYORGY"/AU) AND MYCOBACTER?

=> d

L3   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2004:722914  CAPLUS
DN   141:236625
TI   Inhibitors of mycobacterial serine/threonine protein kinases for
     the treatment of mycobacterial infections
IN   Pato, Janos; Keri, Gyorgy; Orfi, Laszlo; Waczek, Frigyes;
     Horvath, Zoltan; Banhegyi, Peter; Szabadkai, Istavan; Marosfalvi, Jeno;
     Hegymegi-Barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas,
     Axel; Bacher, Gerald; Missio, Andrea; Koul, Anil
PA   Hung.
SO   U.S. Pat. Appl. Publ., 51 pp., Cont.-in-part of Appl. No. PCT/EP03/03697.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 3
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
```

```
     ---------------      ----   --------    --------------------   --------
PI   US 2004171603         A1    20040902    US 2003-715591         20031118
     WO 2002094796         A2    20021128    WO 2002-EP5573         20020521
     WO 2002094796         A3    20031204
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
             GN, GQ, GW, ML, MR, NE, SN, TD, TG
     WO 2003084947         A1    20031016    WO 2003-EP3697         20030409
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI EP 2001-112289        A     20010518
     US 2001-292325P       P     20010522
     US 2001-298902P       P     20010619
     EP 2001-115508        A     20010627
     EP 2002-7923          A     20020409
     WO 2002-EP5573        A2    20020521
     WO 2003-EP3697        A2    20030409
OS   MARPAT 141:236625


=> e orfi laszlo/au
E1            1     ORFI JAN/AU
E2           45     ORFI L/AU
E3          106 --> ORFI LASZLO/AU
E4            1     ORFI S/AU
E5           65     ORFI S D/AU
E6            5     ORFI SARAJ DIN/AU
E7            1     ORFI SARAJDIN/AU
E8            1     ORFIELD A/AU
E9            1     ORFIELD GARY/AU
E10           2     ORFIELD HORACE M/AU
E11           4     ORFIELD M L/AU
E12           1     ORFIELD MARY/AU

=> s e2-e3 and mycobacter?
L4            2 ("ORFI L"/AU OR "ORFI LASZLO"/AU) AND MYCOBACTER?

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5             2 DUP REM L4 (0 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

L5   ANSWER 1 OF 2  BIOSIS  COPYRIGHT (c) 2007 The Thomson Corporation  on STN
AN   2006:247378  BIOSIS
DN   PREV200600248365
TI   Inhibitors of a mycobacterial protein kinase target and their
     conversion into novel drug candidates for Mycobacterium
```

tuberculosis infected patients.
AU Orfi, L. [Reprint Author]; Koul, A.; Hafenbradl, D.; Klebl, B.; Hoppe, E.; Missio, A.; Mueller, G.; Ullrich, A.; Pato, J.; Waczek, F.; Marko, P.; Banhegyi, P.; Greff, Z.; Keri, G.
CS Semmelweis Univ, Dept Pharmaceut Chem, Budapest, Hungary
lorfi@vichem.hu
SO FEBS Journal, (JUL 2005) Vol. 272, No. Suppl. 1, pp. 522.
Meeting Info.: 30th Congress of the Federation-of-European-Biochemical-Societies (FEBS)/9th IUBMB Conference. Budapest, HUNGARY. July 02 -07, 2005. Federat European Biochem Soc; Int Union Biochem Mol Biol.
ISSN: 1742-464X. E-ISSN: 1742-4658.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 26 Apr 2006
Last Updated on STN: 26 Apr 2006

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:722914 CAPLUS
DN 141:236625
TI Inhibitors of mycobacterial serine/threonine protein kinases for the treatment of mycobacterial infections
IN Pato, Janos; Keri, Gyorgy; Orfi, Laszlo; Waczek, Frigyes; Horvath, Zoltan; Banhegyi, Peter; Szabadkai, Istavan; Marosfalvi, Jeno; Hegymegi-Barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas, Axel; Bacher, Gerald; Missio, Andrea; Koul, Anil
PA Hung.
SO U.S. Pat. Appl. Publ., 51 pp., Cont.-in-part of Appl. No. PCT/EP03/03697.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004171603	A1	20040902	US 2003-715591	20031118
	WO 2002094796	A2	20021128	WO 2002-EP5573	20020521
	WO 2002094796	A3	20031204		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2003084947	A1	20031016	WO 2003-EP3697	20030409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	EP 2001-112289	A	20010518		
	US 2001-292325P	P	20010522		
	US 2001-298902P	P	20010619		
	EP 2001-115508	A	20010627		
	EP 2002-7923	A	20020409		
	WO 2002-EP5573	A2	20020521		

WO 2003-EP3697 A2 20030409
OS MARPAT 141:236625
AB Mycobacterial serine/threonine protein kinases, particularly protein kinase G (PknG), are effective therapeutic targets for the treatment of mycobacterial infections. The invention discloses the use of mycobacterial serine/threonine protein kinases for developing methods for detection and determination of these kinases for recognizing and monitoring diseases and for controlling therapy of diseases. Addnl. disclosed are 4,5,6,7-tetrahydrobenzo[b]thiophene compds., benzo[g]quinoxaline compds., and pharmaceutically acceptable salts thereof, and methods of using such compds. and salts thereof for the prophylaxis and/or treatment of virally and/or bacterially induced infections, particularly mycobacteria-induced infections, including opportunistic infections, as well as pharmaceutical compns. containing at least one 4,5,6,7-tetrahydrobenzo[b]thiophene compound and/or benzo[g]quinoxaline compound and/or pharmaceutically acceptable salts thereof in a pharmaceutically acceptable carrier.

=> e waczek frigyes/au
E1 5 WACZEK B/AU
E2 4 WACZEK F/AU
E3 21 --> WACZEK FRIGYES/AU
E4 4 WACZEK S L/AU
E5 1 WACZEL A/AU
E6 1 WACZIARG ROMAIN/AU
E7 9 WACZKOWSKI W/AU
E8 3 WACZKOWSKI WOJCIECH/AU
E9 1 WACZNADZE D/AU
E10 1 WACZUK A/AU
E11 1 WACZUK ADROALDO/AU
E12 1 WACZUL IKOVA I/AU

=> s e2-e3 and mycobacter?
L6 4 ("WACZEK F"/AU OR "WACZEK FRIGYES"/AU) AND MYCOBACTER?

=> d 1-
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L6 ANSWER 1 OF 4 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2006:247378 BIOSIS
DN PREV200600248365
TI Inhibitors of a mycobacterial protein kinase target and their conversion into novel drug candidates for Mycobacterium tuberculosis infected patients.
AU Orfi, L. [Reprint Author]; Koul, A.; Hafenbradl, D.; Klebl, B.; Hoppe, E.; Missio, A.; Mueller, G.; Ullrich, A.; Pato, J.; Waczek, F.; Marko, P.; Banhegyi, P.; Greff, Z.; Keri, G.
CS Semmelweis Univ, Dept Pharmaceut Chem, Budapest, Hungary
lorfi@vichem.hu
SO FEBS Journal, (JUL 2005) Vol. 272, No. Suppl. 1, pp. 522.
Meeting Info.: 30th Congress of the Federation-of-European-Biochemical-Societies (FEBS)/9th IUBMB Conference. Budapest, HUNGARY. July 02 -07, 2005. Federat European Biochem Soc; Int Union Biochem Mol Biol.
ISSN: 1742-464X. E-ISSN: 1742-4658.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 26 Apr 2006
Last Updated on STN: 26 Apr 2006

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:238994 CAPLUS
DN 142:316820

TI Preparation of hetero-bicyclic fused thieno-pyran compounds as antibacterial, antiviral, antitumor, and pharmaceutically active agents

IN Koul, Anil; Klebl, Bert; Mueller, Gerhard; Missio, Andrea; Schwab, Wilfried; Hafenbradl, Doris; Neumann, Lars; Sommer, Marc-Nicola; Mueller, Stefan; Hoppe, Edmund; Freisleben, Achim; Backes, Alexander; Hartung, Christian; Felber, Beatrice; Zech, Birgit; Engkvist, Ola; Keri, Gyoergy; Oerfi, Laszlo; Banhegyi, Peter; Greff, Zoltan; Horvath, Zoltan; Varga, Zoltan; Marko, Peter; Pato, Janos; Szabadkai, Istvan; Szekelyhidi, Zsolt; Waczek, Frigyes

PA Axxima Pharmaceuticals A.-G., Germany

SO PCT Int. Appl., 259 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005023818	A2	20050317	WO 2004-EP10161	20040910
	WO 2005023818	A3	20050825		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004270394	A1	20050317	AU 2004-270394	20040910
	CA 2572750	A1	20050317	CA 2004-2572750	20040910
	EP 1670804	A2	20060621	EP 2004-786934	20040910
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	EP 2003-20616	A	20030910		
	US 2003-502606P	P	20030915		
	EP 2004-4891	A	20040302		
	US 2004-551341P	P	20040310		
	EP 2004-12814	A	20040528		
	US 2004-577043P	P	20040607		
	WO 2004-EP10161	W	20040910		

OS MARPAT 142:316820

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:722914 CAPLUS

DN 141:236625

TI Inhibitors of mycobacterial serine/threonine protein kinases for the treatment of mycobacterial infections

IN Pato, Janos; Keri, Gyorgy; Orfi, Laszlo; Waczek, Frigyes; Horvath, Zoltan; Banhegyi, Peter; Szabadkai, Istavan; Marosfalvi, Jeno; Hegymegi-Barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas, Axel; Bacher, Gerald; Missio, Andrea; Koul, Anil

PA Hung.

SO U.S. Pat. Appl. Publ., 51 pp., Cont.-in-part of Appl. No. PCT/EP03/03697.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004171603	A1	20040902	US 2003-715591	20031118
	WO 2002094796	A2	20021128	WO 2002-EP5573	20020521
	WO 2002094796	A3	20031204		

```
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
             GN, GQ, GW, ML, MR, NE, SN, TD, TG
     WO 2003084947        A1     20031016    WO 2003-EP3697          20030409
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI EP 2001-112289       A      20010518
     US 2001-292325P      P      20010522
     US 2001-298902P      P      20010619
     EP 2001-115508       A      20010627
     EP 2002-7923         A      20020409
     WO 2002-EP5573       A2     20020521
     WO 2003-EP3697       A2     20030409
OS   MARPAT 141:236625

L6   ANSWER 4 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2002:906175  CAPLUS
DN   138:14074
TI   Preparation of benzo[g]quinoxalines for use against infectious diseases
IN   Pato, Janos; Keri, Gyoergy; Oerfi, Laszlo; Waczek, Frigyes;
     Horvath, Zoltan; Banhegyi, Peter; Szabadkai, Istvan; Marosfalvi, Jenoe;
     Hegymegi-barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas,
     Axel; Bacher, Gerald; Daub, Henrik; Obert, Sabine; Kurtenbach, Alexander;
     Habenberger, Peter
PA   Axxima Pharmaceuticals Ag, Germany; et al.
SO   PCT Int. Appl., 237 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 3
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2002094796         A2    20021128    WO 2002-EP5573          20020521
     WO 2002094796         A3    20031204
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
             GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2002312927         A1    20021203    AU 2002-312927          20020521
     US 2004171603         A1    20040902    US 2003-715591          20031118
PRAI EP 2001-112289       A      20010518
     US 2001-292325P      P      20010522
     US 2001-298902P      P      20010619
```

```
     EP 2001-115508        A      20010627
     EP 2002-7923          A      20020409
     WO 2002-EP5573        W      20020521
     WO 2003-EP3697        A2     20030409
OS   MARPAT 138:14074


=> e horvath zoltan/aui
'AUI' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'BIOSIS'
'AUI' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'CAPLUS'
'AUI' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'MEDLINE'
'AUI' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'LIFESCI'
'AUI' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'CABA'
The indicated field code is not available for EXPAND in this
file.  To see a list of valid EXPAND field codes, enter HELP
SFIELDS at an arrow prompt (=>).

=> e horvath zoltan/au
E1            1     HORVATH ZOLAN/AU
E2            1     HORVATH ZOLT/AU
E3          163 --> HORVATH ZOLTAN/AU
E4            2     HORVATH ZOLTAN A/AU
E5            3     HORVATH ZOLTAN GYOERGY/AU
E6            2     HORVATH ZOLTAN GYORGY/AU
E7            1     HORVATH ZOLTAN J/AU
E8            2     HORVATH ZOLTAN JOSEF/AU
E9            4     HORVATH ZOLTAN L/AU
E10           2     HORVATH ZOLTANNE/AU
E11           1     HORVATH ZOLTIN/AU
E12          34     HORVATH ZS/AU

=> s e2-e11 and mycobacter?
L7            4 ("HORVATH ZOLT"/AU OR "HORVATH ZOLTAN"/AU OR "HORVATH ZOLTAN
                A"/AU OR "HORVATH ZOLTAN GYOERGY"/AU OR "HORVATH ZOLTAN GYORGY"/
               AU OR "HORVATH ZOLTAN J"/AU OR "HORVATH ZOLTAN JOSEF"/AU OR "HORV
               ATH ZOLTAN L"/AU OR "HORVATH ZOLTANNE"/AU OR "HORVATH ZOLTIN"/AU)
                AND MYCOBACTER?

=> dup rem l7
PROCESSING COMPLETED FOR L7
L8            4 DUP REM L7 (0 DUPLICATES REMOVED)

=> d bib ab 1-
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L8   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2007:591509  CAPLUS
DN   147:31086
TI   Naphthyridine compounds as ROCK inhibitors, their preparation,
     pharmaceutical compositions, and use in therapy
IN   Mueller, Stefan; Schwab, Wilfried; Klebl, Bert; Hafenbradl, Doris; Hoppe,
     Edmund; Horvath, Zoltan; Keri, Gyoergy; Varga, Zoltan; Oerfi,
     Laszlo; Marosfalvi, Jenoe; Mueller, Gerhard
PA   GPC Biotech A.-G., Germany
SO   PCT Int. Appl., 73pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2007060028        A1    20070531    WO 2006-EP50005         20060102
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
```

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

PRAI EP 2004-31078 A 20041231

OS MARPAT 147:31086

AB The invention relates to naphthyridine compds. of general formula I, which are inhibitors of Rho-associated coiled-coil containing kinases (ROCK protein kinases). In compds. I, R1 and R2 are independently selected from H, halo, OH, alkyl, alkoxy, cycloalkyl, aryl, haloalkyl, aryloxy, etc.; R3 is absent, H, alkyl, cyclopropyl, Ph, benzyl, alkenyl, or alkynyl; R4 is substituted C1-3 alkyl; and X is (=O), or X and R4, together with the atoms to which they are attached, form a nitrogen-containing heterocyclyl or heteroaryl; including stereoisomers, prodrugs, solvates, hydrates, and/or salts thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I as an active ingredient together with at least one pharmaceutically acceptable carrier, excipient and/or diluents, as well as to the use of the compns. for the treatment of conditions responding to inhibition of ROCK kinases, such as cancers, erectile dysfunction, and cardiovascular diseases. The compds. of the invention were prepared by the amidation of the corresponding naphthyridinecarboxylic acid or -carbonyl chloride with the appropriate amine. The compds. of the invention are inhibitors of ROCK1 and ROCK2, e.g., compound II expressed IC50 values of 0.30 μM and 0.38 μM, resp.

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:238994 CAPLUS

DN 142:316820

TI Preparation of hetero-bicyclic fused thieno-pyran compounds as antibacterial, antiviral, antitumor, and pharmaceutically active agents

IN Koul, Anil; Klebl, Bert; Mueller, Gerhard; Missio, Andrea; Schwab, Wilfried; Hafenbradl, Doris; Neumann, Lars; Sommer, Marc-Nicola; Mueller, Stefan; Hoppe, Edmund; Freisleben, Achim; Backes, Alexander; Hartung, Christian; Felber, Beatrice; Zech, Birgit; Engkvist, Ola; Keri, Gyoergy; Oerfi, Laszlo; Banhegyi, Peter; Greff, Zoltan; Horvath, Zoltan; Varga, Zoltan; Marko, Peter; Pato, Janos; Szabadkai, Istvan; Szekelyhidi, Zsolt; Waczek, Frigyes

PA Axxima Pharmaceuticals A.-G., Germany

SO PCT Int. Appl., 259 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005023818	A2	20050317	WO 2004-EP10161	20040910
WO 2005023818	A3	20050825		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	AU 2004270394	A1	20050317	AU 2004-270394	20040910
	CA 2572750	A1	20050317	CA 2004-2572750	20040910
	EP 1670804	A2	20060621	EP 2004-786934	20040910

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRAI	EP 2003-20616	A	20030910
	US 2003-502606P	P	20030915
	EP 2004-4891	A	20040302
	US 2004-551341P	P	20040310
	EP 2004-12814	A	20040528
	US 2004-577043P	P	20040607
	WO 2004-EP10161	W	20040910

OS MARPAT 142:316820

AB Described are hetero-bicyclic compds. such as 4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]thiopyran-3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid amides, or benzo[b]thiophene-3-carboxylic acid amides I, wherein X1 is S, O, NH, substituted nitrogen; Y1-Y4 form with the ring containing X1 a hetero-bicyclic ring system; R1 is H, alkyl, cycloalkyl, heterocycle, alkynyl, substituted Ph, acyl, benzyl; R2 is amide, thioamide, sulfonamide, ester, sulfonyl; R3 is H, acyl, thio-ketone, sulfonyl, amide, thio-amide, diketone-amide, ester, thio-ester; and pharmaceutically acceptable salts thereof, the use of these derivs. for the prophylaxis and/or treatment of various diseases such as infectious diseases, including mycobacteria-induced infections and opportunistic diseases, prion diseases, immunol. diseases, autoimmune diseases, bipolar and clin. disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, as well as compns. containing at least one hetero-bicyclic compound and/or pharmaceutically acceptable salts thereof. Furthermore, reaction procedures for the synthesis of the hetero-bicyclic compound are disclosed. Thus, benzo[b]thiophen-carboxylic acid amide II was prepared and tested in vitro for its inhibitory effect on mycobacterial protein kinase G (IC50 = 0.1-1.0 μM).

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:722914 CAPLUS

DN 141:236625

TI Inhibitors of mycobacterial serine/threonine protein kinases for the treatment of mycobacterial infections

IN Pato, Janos; Keri, Gyorgy; Orfi, Laszlo; Waczek, Frigyes; Horvath, Zoltan; Banhegyi, Peter; Szabadkai, Istavan; Marosfalvi, Jeno; Hegymegi-Barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas, Axel; Bacher, Gerald; Missio, Andrea; Koul, Anil

PA Hung.

SO U.S. Pat. Appl. Publ., 51 pp., Cont.-in-part of Appl. No. PCT/EP03/03697.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004171603	A1	20040902	US 2003-715591	20031118
	WO 2002094796	A2	20021128	WO 2002-EP5573	20020521
	WO 2002094796	A3	20031204		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2003084947 A1 20031016 WO 2003-EP3697 20030409
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI EP 2001-112289 A 20010518
US 2001-292325P P 20010522
US 2001-298902P P 20010619
EP 2001-115508 A 20010627
EP 2002-7923 A 20020409
WO 2002-EP5573 A2 20020521
WO 2003-EP3697 A2 20030409

OS MARPAT 141:236625

AB Mycobacterial serine/threonine protein kinases, particularly protein kinase G (PknG), are effective therapeutic targets for the treatment of mycobacterial infections. The invention discloses the use of mycobacterial serine/threonine protein kinases for developing methods for detection and determination of these kinases for recognizing and monitoring diseases and for controlling therapy of diseases. Addnl. disclosed are 4,5,6,7-tetrahydrobenzo[b]thiophene compds., benzo[g]quinoxaline compds., and pharmaceutically acceptable salts thereof, and methods of using such compds. and salts thereof for the prophylaxis and/or treatment of virally and/or bacterially induced infections, particularly mycobacteria-induced infections, including opportunistic infections, as well as pharmaceutical compns. containing at least one 4,5,6,7-tetrahydrobenzo[b]thiophene compound and/or benzo[g]quinoxaline compound and/or pharmaceutically acceptable salts thereof in a pharmaceutically acceptable carrier.

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:906175 CAPLUS
DN 138:14074
TI Preparation of benzo[g]quinoxalines for use against infectious diseases
IN Pato, Janos; Keri, Gyoergy; Oerfi, Laszlo; Waczek, Frigyes; Horvath, Zoltan; Banhegyi, Peter; Szabadkai, Istvan; Marosfalvi, Jenoe; Hegymegi-barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas, Axel; Bacher, Gerald; Daub, Henrik; Obert, Sabine; Kurtenbach, Alexander; Habenberger, Peter
PA Axxima Pharmaceuticals Ag, Germany; et al.
SO PCT Int. Appl., 237 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002094796	A2	20021128	WO 2002-EP5573	20020521
WO 2002094796	A3	20031204		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	AU 2002312927	A1	20021203	AU 2002-312927	20020521
	US 2004171603	A1	20040902	US 2003-715591	20031118
PRAI	EP 2001-112289	A	20010518		
	US 2001-292325P	P	20010522		
	US 2001-298902P	P	20010619		
	EP 2001-115508	A	20010627		
	EP 2002-7923	A	20020409		
	WO 2002-EP5573	W	20020521		
	WO 2003-EP3697	A2	20030409		

OS MARPAT 138:14074

AB The present invention relates to benzo[g]quinoxaline derivs. (shown as I; e.g. 2,3-bis(2-thienyl)benzo[g]quinoxaline and benzo[g]quinoxalin-2-yl(3-bromophenyl)amine), processes for manufacturing said benzo[g]quinoxaline derivs., the use of the benzo[g]quinoxaline derivs. as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases and opportunistic infections, diabetes, cancer, inflammation, as well as compns. containing at least one benzo[g]quinoxaline derivative and/or pharmaceutically acceptable salt thereof. Further, the present invention is directed to methods for preventing and/or treating of infectious diseases, diabetes, cancer, and inflammation using the inventive benzo[g]quinoxaline derivs. The inventive benzo[g]quinoxaline derivs. exert their antiproliferative effect on M. bovis BCG and M. tuberculosis Erdmann at concns. between <<1 μM and 32 μM. In contrast, growth of E. coli XI-1 blue was not affected by benzo[g]quinoxaline derivs. at concns. >10 μM. The benzo[g]quinoxaline compds. are able to inhibit HI virus replication up to 63% after 6 days at a concentration of 1 μM. 5,10-Dibromo-2-(thiophen-3-yl)-3-(thiophen-2-yl)benzo[g]quinoxaline is able to decrease the activity of the herpes viral target UL-97 by 75%. Results for inhibition of HCMV target RICK for 5 I, of influenza replication for 7 I, of hepatitis B virus for 5 I, of TNFα signaling for 11 I, of human cellular protein kinases (Akt, Abl, PDGFR, Src) for 7 I, of A549 and Jurkat cells for 18 I, of human cellular protein kinase Akt known as a target for diabetes for 4 I, and of human protein kinases SRPK1 and SRPK2 (indicative of hepatitis B virus replication inhibition) for 8 and 1 I, resp., are tabulated. Results for activation of the insulin receptor InsR by 3 I, effect of 2 I on viability of Huh-5-2 replicon cells by the Alamar Blue toxicity assay, effect of 2 I on autonomous replication of hepatitis C virus replicons in the Huh-5-2 cell line by luciferase reporter assay, are tabulated. In I: R1 and R2 = -(CH2)p-NH-(CH2)n-R9, -(CH2)s-S-(CH2)m-R10, -(CH2)m-O-(CH2)p-R11, -(CH2)r-R3, -CH:CH-R11, -(CH2)m-CH(OH)(CH2)p-R11, -(CH2)q-R11, -R9, R10, -R12, -R13, etc. R3, R4, R5, R6, R7, and R8 = -H, -F, -Cl, -Br, -I, -SO3H, -SO3NH2, -(CH2)s-COOR16, -(CH2)p-COOR17, -OR16, -SR16, -NR16R17, -OOCR16, -OOCR17, -NH-CO-R16, -NH-CO-R17, -CO-NH-R16, -CO-NH-R17, -NO2, -N3, -CN, -OCN, -NCO, -SCN, -NCS, CO-R16, CO-R17, -COCN, -CONR16R17, -SOR16, -SO2R16, -SO2R17, -SO3R16, -SO3R17, OCF3. R9, R10, and R11 = -CN, NR16R17, -NHR16, NHR17, etc. R12, R13, R14, and R15 = R3, R4, R5, R6, R16, R17, CH(CO2R16)(CO2R17), CH(CN)(CO2R16), CH(CN)C(O)NHAr (Ar = R14- and R15-substituted phenyl); R16 and R17 = -H, -CH3, -C2H5, -Pr, -CHMe2, -Bu, -C5H11, -C6H13, -cyclo-C6H11, -cyclo-C5H9, -cyclo-C4H7, -cyclo-C3H5, -(CH2)r-CHMe2, -CHMeEt, -CMe3, -CH:CH2, -CH2-CH:CH2, Ph, --CH2Ph, -C2H4Ph, -CH(CN)2, -CF3, -CCl3, -CBr3, -C2F5, -(CH2)r-OH, -CH2F, -CH2Cl, -CH2Br, -CH2I, -CHF2, -CHCl2, -CHBr2, -(CH2)r-SH, -C6H4-CH3, -C6H3Me2, pyridyl, 2-pyrimidinyl, etc. M = 0-6, n = 0-6, p = 0-6, q = 0-6, r = 1-6, s = 0-6. Also claimed are the corresponding N-oxides in position 1 and/or 4 of these compds., the corresponding reduced forms of these compds. wherein the double bond in position 1 and/or 3 is hydrogenated, and pharmaceutically acceptable salts of I. About 42 example prepns. and 406 compds. with characterization data are included. 1H-benzo[g]quinoxaline-2-

one was prepared in 90% yield by dissolving 20 mmol 2,3-diaminonaphthalene in a mixture of 5 mL DMF and 50 mL EtOH and adding 5 mL aqueous solution (50%) of
glyoxalic acid and the mixture was stirred for 2 h at reflux temperature The reaction mixture was cooled to room temperature and the product was filtered, washed two times with Et2O and dried.

```
=> e banhegyi peter/au
E1            5     BANHEGYI P/AU
E2            1     BANHEGYI P G/AU
E3           12 --> BANHEGYI PETER/AU
E4            1     BANHEGYI PETER G/AU
E5            1     BANHEGYI TOTH AGNES/AU
E6            1     BANHEGYIOVA EVA/AU
E7            3     BANHEGYL D/AU
E8            2     BANHEGYL G/AU
E9            1     BANHEGYL M/AU
E10           1     BANHHAM A D/AU
E11           5     BANHIDAI BELA/AU
E12           1     BANHIDAI MIRIAM/AU

=> s e1-e4 and mycobacter?
L9            4 ("BANHEGYI P"/AU OR "BANHEGYI P G"/AU OR "BANHEGYI PETER"/AU OR
                "BANHEGYI PETER G"/AU) AND MYCOBACTER?

=> d 1-
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L9   ANSWER 1 OF 4  BIOSIS  COPYRIGHT (c) 2007 The Thomson Corporation  on STN
AN   2006:247378  BIOSIS
DN   PREV200600248365
TI   Inhibitors of a mycobacterial protein kinase target and their
     conversion into novel drug candidates for Mycobacterium
     tuberculosis infected patients.
AU   Orfi, L. [Reprint Author]; Koul, A.; Hafenbradl, D.; Klebl, B.; Hoppe, E.;
     Missio, A.; Mueller, G.; Ullrich, A.; Pato, J.; Waczek, F.; Marko, P.;
     Banhegyi, P.; Greff, Z.; Keri, G.
CS   Semmelweis Univ, Dept Pharmaceut Chem, Budapest, Hungary
     lorfi@vichem.hu
SO   FEBS Journal, (JUL 2005) Vol. 272, No. Suppl. 1, pp. 522.
     Meeting Info.: 30th Congress of the Federation-of-European-Biochemical-
     Societies (FEBS)/9th IUBMB Conference. Budapest, HUNGARY. July 02 -07,
     2005. Federat European Biochem Soc; Int Union Biochem Mol Biol.
     ISSN: 1742-464X. E-ISSN: 1742-4658.
DT   Conference; (Meeting)
     Conference; Abstract; (Meeting Abstract)
LA   English
ED   Entered STN: 26 Apr 2006
     Last Updated on STN: 26 Apr 2006

L9   ANSWER 2 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2005:238994  CAPLUS
DN   142:316820
TI   Preparation of hetero-bicyclic fused thieno-pyran compounds as
     antibacterial, antiviral, antitumor, and pharmaceutically active agents
IN   Koul, Anil; Klebl, Bert; Mueller, Gerhard; Missio, Andrea; Schwab,
     Wilfried; Hafenbradl, Doris; Neumann, Lars; Sommer, Marc-Nicola; Mueller,
     Stefan; Hoppe, Edmund; Freisleben, Achim; Backes, Alexander; Hartung,
     Christian; Felber, Beatrice; Zech, Birgit; Engkvist, Ola; Keri, Gyoergy;
     Oerfi, Laszlo; Banhegyi, Peter; Greff, Zoltan; Horvath, Zoltan;
     Varga, Zoltan; Marko, Peter; Pato, Janos; Szabadkai, Istvan; Szekelyhidi,
     Zsolt; Waczek, Frigyes
PA   Axxima Pharmaceuticals A.-G., Germany
```

SO PCT Int. Appl., 259 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005023818	A2	20050317	WO 2004-EP10161	20040910
	WO 2005023818	A3	20050825		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004270394	A1	20050317	AU 2004-270394	20040910
	CA 2572750	A1	20050317	CA 2004-2572750	20040910
	EP 1670804	A2	20060621	EP 2004-786934	20040910
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	EP 2003-20616	A	20030910		
	US 2003-502606P	P	20030915		
	EP 2004-4891	A	20040302		
	US 2004-551341P	P	20040310		
	EP 2004-12814	A	20040528		
	US 2004-577043P	P	20040607		
	WO 2004-EP10161	W	20040910		

OS MARPAT 142:316820

L9 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:722914 CAPLUS
DN 141:236625
TI Inhibitors of mycobacterial serine/threonine protein kinases for the treatment of mycobacterial infections
IN Pato, Janos; Keri, Gyorgy; Orfi, Laszlo; Waczek, Frigyes; Horvath, Zoltan; Banhegyi, Peter; Szabadkai, Istavan; Marosfalvi, Jeno; Hegymegi-Barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas, Axel; Bacher, Gerald; Missio, Andrea; Koul, Anil
PA Hung.
SO U.S. Pat. Appl. Publ., 51 pp., Cont.-in-part of Appl. No. PCT/EP03/03697.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004171603	A1	20040902	US 2003-715591	20031118
	WO 2002094796	A2	20021128	WO 2002-EP5573	20020521
	WO 2002094796	A3	20031204		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

```
     WO 2003084947         A1     20031016    WO 2003-EP3697          20030409
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI EP 2001-112289        A      20010518
     US 2001-292325P       P      20010522
     US 2001-298902P       P      20010619
     EP 2001-115508        A      20010627
     EP 2002-7923          A      20020409
     WO 2002-EP5573        A2     20020521
     WO 2003-EP3697        A2     20030409
OS   MARPAT 141:236625

L9   ANSWER 4 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2002:906175  CAPLUS
DN   138:14074
TI   Preparation of benzo[g]quinoxalines for use against infectious diseases
IN   Pato, Janos; Keri, Gyoergy; Oerfi, Laszlo; Waczek, Frigyes; Horvath,
     Zoltan; Banhegyi, Peter; Szabadkai, Istvan; Marosfalvi, Jenoe;
     Hegymegi-barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas,
     Axel; Bacher, Gerald; Daub, Henrik; Obert, Sabine; Kurtenbach, Alexander;
     Habenberger, Peter
PA   Axxima Pharmaceuticals Ag, Germany; et al.
SO   PCT Int. Appl., 237 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 3
     PATENT NO.            KIND   DATE        APPLICATION NO.         DATE
     ---------------       ----   --------    --------------------    --------
PI   WO 2002094796         A2     20021128    WO 2002-EP5573          20020521
     WO 2002094796         A3     20031204
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
             GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2002312927         A1     20021203    AU 2002-312927          20020521
     US 2004171603         A1     20040902    US 2003-715591          20031118
PRAI EP 2001-112289        A      20010518
     US 2001-292325P       P      20010522
     US 2001-298902P       P      20010619
     EP 2001-115508        A      20010627
     EP 2002-7923          A      20020409
     WO 2002-EP5573        W      20020521
     WO 2003-EP3697        A2     20030409
OS   MARPAT 138:14074


=> e szabadkai istavan/au
E1            1     SZABADKAI GYRGY/AU
E2            6     SZABADKAI I/AU
```

```
E3            1 --> SZABADKAI ISTAVAN/AU
E4           25     SZABADKAI ISTVAN/AU
E5            1     SZABADKAI SZADVARI SAROLTA/AU
E6            3     SZABADKAI YOURI/AU
E7            1     SZABADKAY LASZLO/AU
E8            1     SZABADOS/AU
E9           41     SZABADOS A/AU
E10          26     SZABADOS AGNES/AU
E11           2     SZABADOS ANDRAS/AU
E12           4     SZABADOS ANDREAS/AU

=> s e2-e4 and mycobacter?
L10           3 ("SZABADKAI I"/AU OR "SZABADKAI ISTAVAN"/AU OR "SZABADKAI ISTVAN
                "/AU) AND MYCOBACTER?

=> d 1-
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L10  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2005:238994  CAPLUS
DN   142:316820
TI   Preparation of hetero-bicyclic fused thieno-pyran compounds as
     antibacterial, antiviral, antitumor, and pharmaceutically active agents
IN   Koul, Anil; Klebl, Bert; Mueller, Gerhard; Missio, Andrea; Schwab,
     Wilfried; Hafenbradl, Doris; Neumann, Lars; Sommer, Marc-Nicola; Mueller,
     Stefan; Hoppe, Edmund; Freisleben, Achim; Backes, Alexander; Hartung,
     Christian; Felber, Beatrice; Zech, Birgit; Engkvist, Ola; Keri, Gyoergy;
     Oerfi, Laszlo; Banhegyi, Peter; Greff, Zoltan; Horvath, Zoltan; Varga,
     Zoltan; Marko, Peter; Pato, Janos; Szabadkai, Istvan;
     Szekelyhidi, Zsolt; Waczek, Frigyes
PA   Axxima Pharmaceuticals A.-G., Germany
SO   PCT Int. Appl., 259 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
PI   WO 2005023818         A2    20050317    WO 2004-EP10161          20040910
     WO 2005023818         A3    20050825
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     AU 2004270394         A1    20050317    AU 2004-270394           20040910
     CA 2572750            A1    20050317    CA 2004-2572750          20040910
     EP 1670804            A2    20060621    EP 2004-786934           20040910
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
PRAI EP 2003-20616         A     20030910
     US 2003-502606P       P     20030915
     EP 2004-4891          A     20040302
     US 2004-551341P       P     20040310
     EP 2004-12814         A     20040528
     US 2004-577043P       P     20040607
     WO 2004-EP10161       W     20040910
OS   MARPAT 142:316820
```

L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:722914 CAPLUS
DN 141:236625
TI Inhibitors of mycobacterial serine/threonine protein kinases for the treatment of mycobacterial infections
IN Pato, Janos; Keri, Gyorgy; Orfi, Laszlo; Waczek, Frigyes; Horvath, Zoltan; Banhegyi, Peter; Szabadkai, Istavan; Marosfalvi, Jeno; Hegymegi-Barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas, Axel; Bacher, Gerald; Missio, Andrea; Koul, Anil
PA Hung.
SO U.S. Pat. Appl. Publ., 51 pp., Cont.-in-part of Appl. No. PCT/EP03/03697.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004171603	A1	20040902	US 2003-715591	20031118
	WO 2002094796	A2	20021128	WO 2002-EP5573	20020521
	WO 2002094796	A3	20031204		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2003084947	A1	20031016	WO 2003-EP3697	20030409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI	EP 2001-112289	A	20010518
	US 2001-292325P	P	20010522
	US 2001-298902P	P	20010619
	EP 2001-115508	A	20010627
	EP 2002-7923	A	20020409
	WO 2002-EP5573	A2	20020521
	WO 2003-EP3697	A2	20030409

OS MARPAT 141:236625

L10 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:906175 CAPLUS
DN 138:14074
TI Preparation of benzo[g]quinoxalines for use against infectious diseases
IN Pato, Janos; Keri, Gyoergy; Oerfi, Laszlo; Waczek, Frigyes; Horvath, Zoltan; Banhegyi, Peter; Szabadkai, Istvan; Marosfalvi, Jenoe; Hegymegi-barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas, Axel; Bacher, Gerald; Daub, Henrik; Obert, Sabine; Kurtenbach, Alexander; Habenberger, Peter
PA Axxima Pharmaceuticals Ag, Germany; et al.
SO PCT Int. Appl., 237 pp.
CODEN: PIXXD2
DT Patent

```
LA   English
FAN.CNT 3
     PATENT NO.            KIND   DATE        APPLICATION NO.          DATE
     ---------------       ----   --------    --------------------     --------
PI   WO 2002094796          A2    20021128    WO 2002-EP5573           20020521
     WO 2002094796          A3    20031204
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
             GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2002312927          A1    20021203    AU 2002-312927           20020521
     US 2004171603          A1    20040902    US 2003-715591           20031118
PRAI EP 2001-112289         A     20010518
     US 2001-292325P        P     20010522
     US 2001-298902P        P     20010619
     EP 2001-115508         A     20010627
     EP 2002-7923           A     20020409
     WO 2002-EP5573         W     20020521
     WO 2003-EP3697         A2    20030409
OS   MARPAT 138:14074


=> e marosfalvi jeno/aui
'AUI' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'BIOSIS'
'AUI' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'CAPLUS'
'AUI' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'CABA'
'AUI' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'LIFESCI'
'AUI' IS NOT A VALID EXPAND FIELD CODE FOR FILE 'MEDLINE'
The indicated field code is not available for EXPAND in this
file.  To see a list of valid EXPAND field codes, enter HELP
SFIELDS at an arrow prompt (=>).

=> e marosfalvi jeno/au
E1            6     MAROSFALVI J/AU
E2            6     MAROSFALVI JANOS/AU
E3            9 --> MAROSFALVI JENO/AU
E4            5     MAROSFALVI JENOE/AU
E5            1     MAROSFALVI S/AU
E6           11     MAROSFI S/AU
E7            1     MAROSFI SANDOR/AU
E8            2     MAROSFOEI B/AU
E9            2     MAROSFOI B/AU
E10           2     MAROSFOI B B/AU
E11           1     MAROSFOI L I/AU
E12           1     MAROSFOI L L/AU

=> s e1-e4 and mycobacter?
L11           3 ("MAROSFALVI J"/AU OR "MAROSFALVI JANOS"/AU OR "MAROSFALVI JENO"
                /AU OR "MAROSFALVI JENOE"/AU) AND MYCOBACTER?

=> d 1-
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L11  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2007:591509  CAPLUS
DN   147:31086
TI   Naphthyridine compounds as ROCK inhibitors, their preparation,
     pharmaceutical compositions, and use in therapy
```

IN Mueller, Stefan; Schwab, Wilfried; Klebl, Bert; Hafenbradl, Doris; Hoppe, Edmund; Horvath, Zoltan; Keri, Gyoergy; Varga, Zoltan; Oerfi, Laszlo; Marosfalvi, Jenoe; Mueller, Gerhard
PA GPC Biotech A.-G., Germany
SO PCT Int. Appl., 73pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007060028	A1	20070531	WO 2006-EP50005	20060102

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI EP 2004-31078 A 20041231
OS MARPAT 147:31086
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:722914 CAPLUS
DN 141:236625
TI Inhibitors of mycobacterial serine/threonine protein kinases for the treatment of mycobacterial infections
IN Pato, Janos; Keri, Gyorgy; Orfi, Laszlo; Waczek, Frigyes; Horvath, Zoltan; Banhegyi, Peter; Szabadkai, Istavan; Marosfalvi, Jeno; Hegymegi-Barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas, Axel; Bacher, Gerald; Missio, Andrea; Koul, Anil
PA Hung.
SO U.S. Pat. Appl. Publ., 51 pp., Cont.-in-part of Appl. No. PCT/EP03/03697.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004171603	A1	20040902	US 2003-715591	20031118
WO 2002094796	A2	20021128	WO 2002-EP5573	20020521
WO 2002094796	A3	20031204		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2003084947	A1	20031016	WO 2003-EP3697	20030409

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

```
            PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI EP 2001-112289       A     20010518
     US 2001-292325P      P     20010522
     US 2001-298902P      P     20010619
     EP 2001-115508       A     20010627
     EP 2002-7923         A     20020409
     WO 2002-EP5573       A2    20020521
     WO 2003-EP3697       A2    20030409
OS   MARPAT 141:236625

L11  ANSWER 3 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2002:906175  CAPLUS
DN   138:14074
TI   Preparation of benzo[g]quinoxalines for use against infectious diseases
IN   Pato, Janos; Keri, Gyoergy; Oerfi, Laszlo; Waczek, Frigyes; Horvath,
     Zoltan; Banhegyi, Peter; Szabadkai, Istvan; Marosfalvi, Jenoe;
     Hegymegi-barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas,
     Axel; Bacher, Gerald; Daub, Henrik; Obert, Sabine; Kurtenbach, Alexander;
     Habenberger, Peter
PA   Axxima Pharmaceuticals Ag, Germany; et al.
SO   PCT Int. Appl., 237 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 3
     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
PI   WO 2002094796        A2     20021128    WO 2002-EP5573           20020521
     WO 2002094796        A3     20031204
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
             GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2002312927         A1     20021203    AU 2002-312927           20020521
     US 2004171603         A1     20040902    US 2003-715591           20031118
PRAI EP 2001-112289       A      20010518
     US 2001-292325P      P      20010522
     US 2001-298902P      P      20010619
     EP 2001-115508       A      20010627
     EP 2002-7923         A      20020409
     WO 2002-EP5573       W      20020521
     WO 2003-EP3697       A2     20030409
OS   MARPAT 138:14074


=> e hegymegi-barakonyi balint/au
E1            4     HEGYMEGI P/AU
E2            5     HEGYMEGI PETER/AU
E3            0 --> HEGYMEGI-BARAKONYI BALINT/AU
E4            1     HEGYOVA E/AU
E5            1     HEGYVARA C/AU
E6            1     HEGYVARA CS/AU
E7            1     HEGYVARI/AU
```

```
E8            2      HEGYVARI C/AU
E9            2      HEGYVARI CS/AU
E10           1      HEGYVARI CSABA/AU
E11          56      HEGYVARY C/AU
E12           1      HEGYVARY CS/AU

=> e szekelyhidi zsolt/au
E1            8      SZEKELYHIDI T/AU
E2            3      SZEKELYHIDI Z/AU
E3           13 --> SZEKELYHIDI ZSOLT/AU
E4            2      SZEKELYHIDY E H/AU
E5            1      SZEKELYI GHEORGHE A/AU
E6            2      SZEKELYI M/AU
E7            4      SZEKELYI MARIA/AU
E8            1      SZEKELYNE E B/AU
E9            1      SZEKELYNE ESZTER RADICS L/AU
E10           3      SZEKELYNE PECSI ZSUZSA/AU
E11           1      SZEKENDI M K/AU
E12           1      SZEKENDI MARILYN K/AU

=> s e2-e3 and mycobacter?
L12           3 ("SZEKELYHIDI Z"/AU OR "SZEKELYHIDI ZSOLT"/AU) AND MYCOBACTER?

=> d 1-
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L12  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2005:238994  CAPLUS
DN   142:316820
TI   Preparation of hetero-bicyclic fused thieno-pyran compounds as
     antibacterial, antiviral, antitumor, and pharmaceutically active agents
IN   Koul, Anil; Klebl, Bert; Mueller, Gerhard; Missio, Andrea; Schwab,
     Wilfried; Hafenbradl, Doris; Neumann, Lars; Sommer, Marc-Nicola; Mueller,
     Stefan; Hoppe, Edmund; Freisleben, Achim; Backes, Alexander; Hartung,
     Christian; Felber, Beatrice; Zech, Birgit; Engkvist, Ola; Keri, Gyoergy;
     Oerfi, Laszlo; Banhegyi, Peter; Greff, Zoltan; Horvath, Zoltan; Varga,
     Zoltan; Marko, Peter; Pato, Janos; Szabadkai, Istvan; Szekelyhidi,
     Zsolt; Waczek, Frigyes
PA   Axxima Pharmaceuticals A.-G., Germany
SO   PCT Int. Appl., 259 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2005023818        A2    20050317    WO 2004-EP10161         20040910
     WO 2005023818        A3    20050825
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW:  BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     AU 2004270394        A1    20050317    AU 2004-270394          20040910
     CA 2572750           A1    20050317    CA 2004-2572750         20040910
     EP 1670804           A2    20060621    EP 2004-786934          20040910
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
```

PRAI EP 2003-20616 A 20030910
US 2003-502606P P 20030915
EP 2004-4891 A 20040302
US 2004-551341P P 20040310
EP 2004-12814 A 20040528
US 2004-577043P P 20040607
WO 2004-EP10161 W 20040910
OS MARPAT 142:316820

L12 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:722914 CAPLUS
DN 141:236625
TI Inhibitors of mycobacterial serine/threonine protein kinases for the treatment of mycobacterial infections
IN Pato, Janos; Keri, Gyorgy; Orfi, Laszlo; Waczek, Frigyes; Horvath, Zoltan; Banhegyi, Peter; Szabadkai, Istavan; Marosfalvi, Jeno; Hegymegi-Barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas, Axel; Bacher, Gerald; Missio, Andrea; Koul, Anil
PA Hung.
SO U.S. Pat. Appl. Publ., 51 pp., Cont.-in-part of Appl. No. PCT/EP03/03697.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004171603	A1	20040902	US 2003-715591	20031118
WO 2002094796	A2	20021128	WO 2002-EP5573	20020521
WO 2002094796	A3	20031204		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2003084947	A1	20031016	WO 2003-EP3697	20030409

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI EP 2001-112289 A 20010518
US 2001-292325P P 20010522
US 2001-298902P P 20010619
EP 2001-115508 A 20010627
EP 2002-7923 A 20020409
WO 2002-EP5573 A2 20020521
WO 2003-EP3697 A2 20030409
OS MARPAT 141:236625

L12 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:906175 CAPLUS
DN 138:14074
TI Preparation of benzo[g]quinoxalines for use against infectious diseases
IN Pato, Janos; Keri, Gyoergy; Oerfi, Laszlo; Waczek, Frigyes; Horvath,

```
     Zoltan; Banhegyi, Peter; Szabadkai, Istvan; Marosfalvi, Jenoe;
     Hegymegi-barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan;
     Choidas, Axel; Bacher, Gerald; Daub, Henrik; Obert, Sabine; Kurtenbach,
     Alexander; Habenberger, Peter
PA   Axxima Pharmaceuticals Ag, Germany; et al.
SO   PCT Int. Appl., 237 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 3
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2002094796        A2    20021128    WO 2002-EP5573          20020521
     WO 2002094796        A3    20031204
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
             GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2002312927        A1    20021203    AU 2002-312927          20020521
     US 2004171603        A1    20040902    US 2003-715591          20031118
PRAI EP 2001-112289       A     20010518
     US 2001-292325P      P     20010522
     US 2001-298902P      P     20010619
     EP 2001-115508       A     20010627
     EP 2002-7923         A     20020409
     WO 2002-EP5573       W     20020521
     WO 2003-EP3697       A2    20030409
OS   MARPAT 138:14074


=> e greff zoltan/au
E1          12     GREFF STEPHANE/AU
E2           5     GREFF Z/AU
E3          55 --> GREFF ZOLTAN/AU
E4          35     GREFFARD A/AU
E5          19     GREFFARD ANNE/AU
E6           1     GREFFARD B/AU
E7           2     GREFFARD J/AU
E8           4     GREFFARD JACQUES/AU
E9           3     GREFFARD SANDRINE/AU
E10          2     GREFFE A/AU
E11         12     GREFFE ANDRE/AU
E12          1     GREFFE ANTOINETTE/AU

=> s e2-e3 and mycobacter?
L13          5 ("GREFF Z"/AU OR "GREFF ZOLTAN"/AU) AND MYCOBACTER?

=> d 1-
YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y

L13  ANSWER 1 OF 5  BIOSIS  COPYRIGHT (c) 2007 The Thomson Corporation  on STN
AN   2006:247378  BIOSIS
DN   PREV200600248365
TI   Inhibitors of a mycobacterial protein kinase target and their
     conversion into novel drug candidates for Mycobacterium
     tuberculosis infected patients.
AU   Orfi, L. [Reprint Author]; Koul, A.; Hafenbradl, D.; Klebl, B.; Hoppe, E.;
     Missio, A.; Mueller, G.; Ullrich, A.; Pato, J.; Waczek, F.; Marko, P.;
```

Banhegyi, P.; Greff, Z.; Keri, G.
CS Semmelweis Univ, Dept Pharmaceut Chem, Budapest, Hungary
lorfi@vichem.hu
SO FEBS Journal, (JUL 2005) Vol. 272, No. Suppl. 1, pp. 522.
Meeting Info.: 30th Congress of the Federation-of-European-Biochemical-Societies (FEBS)/9th IUBMB Conference. Budapest, HUNGARY. July 02 -07, 2005. Federat European Biochem Soc; Int Union Biochem Mol Biol.
ISSN: 1742-464X. E-ISSN: 1742-4658.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 26 Apr 2006
Last Updated on STN: 26 Apr 2006

L13 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:888148 CAPLUS
DN 145:293025
TI Benzo[2,3]azepino[4,5-b]indol-6-ones as kinase or phosphatase inhibitors, their preparation, pharmaceutical compositions, and use against infectious diseases
IN Klebl, Bert; Neumann, Lars; Hafenbradl, Doris; Greff, Zoltan; Keri, Gyoergy; Oerfi, Laszlo
PA Gpc Biotech AG, Germany
SO PCT Int. Appl., 67pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006089874	A1	20060831	WO 2006-EP60100	20060220

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI EP 2005-3763 A 20050222
OS MARPAT 145:293025
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:238994 CAPLUS
DN 142:316820
TI Preparation of hetero-bicyclic fused thieno-pyran compounds as antibacterial, antiviral, antitumor, and pharmaceutically active agents
IN Koul, Anil; Klebl, Bert; Mueller, Gerhard; Missio, Andrea; Schwab, Wilfried; Hafenbradl, Doris; Neumann, Lars; Sommer, Marc-Nicola; Mueller, Stefan; Hoppe, Edmund; Freisleben, Achim; Backes, Alexander; Hartung, Christian; Felber, Beatrice; Zech, Birgit; Engkvist, Ola; Keri, Gyoergy; Oerfi, Laszlo; Banhegyi, Peter; Greff, Zoltan; Horvath, Zoltan; Varga, Zoltan; Marko, Peter; Pato, Janos; Szabadkai, Istvan; Szekelyhidi, Zsolt; Waczek, Frigyes
PA Axxima Pharmaceuticals A.-G., Germany
SO PCT Int. Appl., 259 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005023818	A2	20050317	WO 2004-EP10161	20040910
	WO 2005023818	A3	20050825		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004270394	A1	20050317	AU 2004-270394	20040910
	CA 2572750	A1	20050317	CA 2004-2572750	20040910
	EP 1670804	A2	20060621	EP 2004-786934	20040910
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	EP 2003-20616	A	20030910		
	US 2003-502606P	P	20030915		
	EP 2004-4891	A	20040302		
	US 2004-551341P	P	20040310		
	EP 2004-12814	A	20040528		
	US 2004-577043P	P	20040607		
	WO 2004-EP10161	W	20040910		

OS MARPAT 142:316820

L13 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:722914 CAPLUS
DN 141:236625
TI Inhibitors of mycobacterial serine/threonine protein kinases for the treatment of mycobacterial infections
IN Pato, Janos; Keri, Gyorgy; Orfi, Laszlo; Waczek, Frigyes; Horvath, Zoltan; Banhegyi, Peter; Szabadkai, Istavan; Marosfalvi, Jeno; Hegymegi-Barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas, Axel; Bacher, Gerald; Missio, Andrea; Koul, Anil
PA Hung.
SO U.S. Pat. Appl. Publ., 51 pp., Cont.-in-part of Appl. No. PCT/EP03/03697. CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004171603	A1	20040902	US 2003-715591	20031118
	WO 2002094796	A2	20021128	WO 2002-EP5573	20020521
	WO 2002094796	A3	20031204		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2003084947	A1	20031016	WO 2003-EP3697	20030409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

```
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI EP 2001-112289       A     20010518
     US 2001-292325P      P     20010522
     US 2001-298902P      P     20010619
     EP 2001-115508       A     20010627
     EP 2002-7923         A     20020409
     WO 2002-EP5573       A2    20020521
     WO 2003-EP3697       A2    20030409
OS   MARPAT 141:236625

L13  ANSWER 5 OF 5  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2002:906175  CAPLUS
DN   138:14074
TI   Preparation of benzo[g]quinoxalines for use against infectious diseases
IN   Pato, Janos; Keri, Gyoergy; Oerfi, Laszlo; Waczek, Frigyes; Horvath,
     Zoltan; Banhegyi, Peter; Szabadkai, Istvan; Marosfalvi, Jenoe;
     Hegymegi-barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan;
     Choidas, Axel; Bacher, Gerald; Daub, Henrik; Obert, Sabine; Kurtenbach,
     Alexander; Habenberger, Peter
PA   Axxima Pharmaceuticals Ag, Germany; et al.
SO   PCT Int. Appl., 237 pp.
     CODEN: PIXXD2
DT   Patent
LA   English.
FAN.CNT 3
     PATENT NO.           KIND   DATE      APPLICATION NO.          DATE
     ---------------      ----   --------  ---------------------    --------
PI   WO 2002094796         A2    20021128  WO 2002-EP5573           20020521
     WO 2002094796         A3    20031204
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
             GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2002312927         A1    20021203  AU 2002-312927           20020521
     US 2004171603         A1    20040902  US 2003-715591           20031118
PRAI EP 2001-112289       A     20010518
     US 2001-292325P      P     20010522
     US 2001-298902P      P     20010619
     EP 2001-115508       A     20010627
     EP 2002-7923         A     20020409
     WO 2002-EP5573       W     20020521
     WO 2003-EP3697       A2    20030409
OS   MARPAT 138:14074


=> e choidas axel/au
E1            1     CHOICHIRO OZU/AU
E2           13     CHOIDAS A/AU
E3           27 --> CHOIDAS AXEL/AU
E4            1     CHOIDAS DIONYSIOS/AU
E5            2     CHOIDAS M/AU
```

```
E6            2      CHOIDAS MELANIE/AU
E7            4      CHOIDASH B/AU
E8            1      CHOIDERA P/AU
E9            1      CHOIDINI G/AU
E10           1      CHOIDINI GERMANA/AU
E11           1      CHOIDINI R J/AU
E12           1      CHOIE C G/AU

=> s e2-e3 and mycobacter?
L14          12 ("CHOIDAS A"/AU OR "CHOIDAS AXEL"/AU) AND MYCOBACTER?

=> d 1-
YOU HAVE REQUESTED DATA FROM 12 ANSWERS - CONTINUE? Y/(N):y

L14  ANSWER 1 OF 12  BIOSIS  COPYRIGHT (c) 2007 The Thomson Corporation  on STN
AN   2001:440206  BIOSIS
DN   PREV200100440206
TI   'Serine/threonine protein kinases PknF and PknG of Mycobacterium
     tuberculosis: Characterization and localization.
AU   Koul, Anil; Choidas, Axel; Tyagi, Anil K.; Drlica, Karl; Singh,
     Yogendra [Reprint author]; Ullrich, Axel
CS   Centre for Biochemical Technology, Mall Road, Delhi, 110 007, India
     ysingh@cbt.res.in
SO   Microbiology (Reading), (August, 2001) Vol. 147, No. 8, pp. 2307-2314.
     print.
     ISSN: 1350-0872.
DT   Article
LA   English
ED   Entered STN: 19 Sep 2001
     Last Updated on STN: 22 Feb 2002

L14  ANSWER 2 OF 12  BIOSIS  COPYRIGHT (c) 2007 The Thomson Corporation  on STN
AN   2000:439757  BIOSIS
DN   PREV200000439757
TI   Cloning and characterization of secretory tyrosine phosphatases of
     Mycobacterium tuberculosis.
AU   Koul, Anil; Choidas, Axel; Treder, Martin; Tyagi, Anil K.;
     Drlica, Karl; Singh, Yogendra; Ullrich, Axel [Reprint author]
CS   Department of Molecular Biology, Max-Planck-Institut fuer Biochemie, Am
     Klopferspitz 18A, 82152, Martinsried, Germany
SO   Journal of Bacteriology, (October, 2000) Vol. 182, No. 19, pp. 5425-5432.
     print.
     CODEN: JOBAAY. ISSN: 0021-9193.
DT   Article
LA   English
ED   Entered STN: 18 Oct 2000
     Last Updated on STN: 10 Jan 2002

L14  ANSWER 3 OF 12  CABA COPYRIGHT 2007 CABI on STN
AN   2001:124449  CABA
DN   20013123913
TI   Serine/threonine protein kinases PknF and PknG of Mycobacterium
     tuberculosis: characterization and localization
AU   Anil Koul; Choidas, A.; Tyagi, A. K.; Drlica, K.; Yogendra
     Singh; Ullrich, A.; Koul, A.; Singh, Y.
CS   Centre for Biochemical Technology, Mall Road, Delhi-110 007, India.
SO   Microbiology (Reading), (2001) Vol. 147, No. 8, pp. 2307-2314. 34 ref.
     Publisher: Society for General Microbiology. Reading
     ISSN: 1350-0872
CY   United Kingdom
DT   Journal
LA   English
ED   Entered STN: 1 Nov 2001
     Last Updated on STN: 1 Nov 2001
```

L14 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:722914 CAPLUS
DN 141:236625
TI Inhibitors of mycobacterial serine/threonine protein kinases for the treatment of mycobacterial infections
IN Pato, Janos; Keri, Gyorgy; Orfi, Laszlo; Waczek, Frigyes; Horvath, Zoltan; Banhegyi, Peter; Szabadkai, Istavan; Marosfalvi, Jeno; Hegymegi-Barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas, Axel; Bacher, Gerald; Missio, Andrea; Koul, Anil
PA Hung.
SO U.S. Pat. Appl. Publ., 51 pp., Cont.-in-part of Appl. No. PCT/EP03/03697.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004171603	A1	20040902	US 2003-715591	20031118
	WO 2002094796	A2	20021128	WO 2002-EP5573	20020521
	WO 2002094796	A3	20031204		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2003084947	A1	20031016	WO 2003-EP3697	20030409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI EP 2001-112289 A 20010518
US 2001-292325P P 20010522
US 2001-298902P P 20010619
EP 2001-115508 A 20010627
EP 2002-7923 A 20020409
WO 2002-EP5573 A2 20020521
WO 2003-EP3697 A2 20030409
OS MARPAT 141:236625

L14 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:818414 CAPLUS
DN 139:317414
TI 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections
IN Missio, Andrea; Bacher, Gerald; Koul, Anil; Choidas, Axel
PA Axxima Pharmaceuticals A.-G., Germany
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084947	A1	20031016	WO 2003-EP3697	20030409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003224054	A1	20031020	AU 2003-224054	20030409
	EP 1492783	A1	20050105	EP 2003-720441	20030409
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2004171603	A1	20040902	US 2003-715591	20031118
PRAI	EP 2002-7923	A	20020409		
	EP 2001-112289	A	20010518		
	US 2001-292325P	P	20010522		
	US 2001-298902P	P	20010619		
	EP 2001-115508	A	20010627		
	WO 2002-EP5573	A2	20020521		
	WO 2003-EP3697	W	20030409		

OS MARPAT 139:317414
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:906175 CAPLUS
DN 138:14074
TI Preparation of benzo[g]quinoxalines for use against infectious diseases
IN Pato, Janos; Keri, Gyoergy; Oerfi, Laszlo; Waczek, Frigyes; Horvath, Zoltan; Banhegyi, Peter; Szabadkai, Istvan; Marosfalvi, Jenoe; Hegymegi-barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas, Axel; Bacher, Gerald; Daub, Henrik; Obert, Sabine; Kurtenbach, Alexander; Habenberger, Peter
PA Axxima Pharmaceuticals Ag, Germany; et al.
SO PCT Int. Appl., 237 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002094796	A2	20021128	WO 2002-EP5573	20020521
	WO 2002094796	A3	20031204		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002312927	A1	20021203	AU 2002-312927	20020521
	US 2004171603	A1	20040902	US 2003-715591	20031118
PRAI	EP 2001-112289	A	20010518		
	US 2001-292325P	P	20010522		
	US 2001-298902P	P	20010619		
	EP 2001-115508	A	20010627		
	EP 2002-7923	A	20020409		

WO 2002-EP5573 W 20020521
WO 2003-EP3697 A2 20030409
OS MARPAT 138:14074

L14 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:630018 CAPLUS
DN 136:81742
TI Serine/threonine protein kinase PknF and PknG of Mycobacterium tuberculosis: characterization and localization
AU Koul, Anil; Choidas, Axel; Tyagi, Anil K.; Drlica, Karl; Singh, Yogendra; Ullrich, Axel
CS Centre for Biochemical Technology, Delhi, 110 007, India
SO Microbiology (Reading, United Kingdom) (2001), 147(8), 2307-2314
CODEN: MROBEO; ISSN: 1350-0872
PB Society for General Microbiology
DT Journal
LA English
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:688820 CAPLUS
DN 134:26828
TI Cloning and characterization of secretory tyrosine phosphatases of Mycobacterium tuberculosis
AU Koul, Anil; Choidas, Axel; Treder, Martin; Tyagi, Anil K.; Drlica, Karl; Singh, Yogendra; Ullrich, Axel
CS Department of Molecular Biology, Max-Planck-Institut fur Biochemie, Martinsried, 82152, Germany
SO Journal of Bacteriology (2000), 182(19), 5425-5432
CODEN: JOBAAY; ISSN: 0021-9193
PB American Society for Microbiology
DT Journal
LA English
RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 9 OF 12 LIFESCI COPYRIGHT 2007 CSA on STN
AN 2002:24332 LIFESCI
TI Serine/threonine protein kinases PknF and PknG of Mycobacterium tuberculosis: characterization and localization
AU Koul, A.; Choidas, A.; Tyagi, A.K.; Drlica, K.; Singh, Y.*; Ullrich, A.
CS Centre for Biochemical Technology, Mall Road, Delhi-110 007, India; E-mail: ysingh@cbt.res.in
SO Microbiology, (20010800) vol. 147, no. 8, pp. 2307-2314.
ISSN: 1350-0872.
DT Journal
FS J
LA English
SL English

L14 ANSWER 10 OF 12 LIFESCI COPYRIGHT 2007 CSA on STN
AN 2001:45403 LIFESCI
TI Cloning and Characterization of Secretory Tyrosine Phosphatases of Mycobacterium tuberculosis
AU Koul, A.; Choidas, A.; Treder, M.; Tyagi, A.K.; Drlica, K.; Singh, Y.; Ullrich, A.
CS Department of Molecular Biology, Max-Planck-Institut fuer Biochemie, Am Klopferspitz 18A, 82152 Martinsried, Germany; E-mail: ullrich@biochem.mpg.de
SO Journal of Bacteriology [J. Bacteriol.], (20001000) vol. 182, no. 19, pp. 5425-5432.
ISSN: 0021-9193.

DT Journal
FS G; J; N
LA English
SL English

L14 ANSWER 11 OF 12 MEDLINE on STN
AN 2001477954 MEDLINE
DN PubMed ID: 11496007
TI Serine/threonine protein kinases PknF and PknG of Mycobacterium tuberculosis: characterization and localization.
AU Koul A; Choidas A; Tyagi A K; Drlica K; Singh Y; Ullrich A
CS Centre for Biochemical Technology, Mall Road, Delhi-110 007, India.
SO Microbiology (Reading, England), (2001 Aug) Vol. 147, No. Pt 8, pp. 2307-14.
Journal code: 9430468. ISSN: 1350-0872.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200112
ED Entered STN: 28 Aug 2001
Last Updated on STN: 21 Jan 2002
Entered Medline: 4 Dec 2001

L14 ANSWER 12 OF 12 MEDLINE on STN
AN 2001010953 MEDLINE
DN PubMed ID: 10986245
TI Cloning and characterization of secretory tyrosine phosphatases of Mycobacterium tuberculosis.
AU Koul A; Choidas A; Treder M; Tyagi A K; Drlica K; Singh Y; Ullrich A
CS Department of Molecular Biology, Max-Planck-Institut fur Biochemie, 82152 Martinsried, Germany.
SO Journal of bacteriology, (2000 Oct) Vol. 182, No. 19, pp. 5425-32.
Journal code: 2985120R. ISSN: 0021-9193.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200010
ED Entered STN: 22 Mar 2001
Last Updated on STN: 22 Mar 2001
Entered Medline: 24 Oct 2000

=> e bacher gerald/au
E1 4 BACHER G DAVID/AU
E2 12 BACHER G J/AU
E3 31 --> BACHER GERALD/AU
E4 1 BACHER GERALD D/AU
E5 13 BACHER GERD/AU
E6 3 BACHER GERD U/AU
E7 1 BACHER GERHARD/AU
E8 11 BACHER GEROLD/AU
E9 1 BACHER GIL N/AU
E10 1 BACHER GOTTIFRIED/AU
E11 1 BACHER GUILLAUME/AU
E12 46 BACHER H/AU

=> s e1-e4 and mycobacter?
L15 7 ("BACHER G DAVID"/AU OR "BACHER G J"/AU OR "BACHER GERALD"/AU OR "BACHER GERALD D"/AU) AND MYCOBACTER?

```
=> d 1-
YOU HAVE REQUESTED DATA FROM 7 ANSWERS - CONTINUE? Y/(N):y

L15  ANSWER 1 OF 7  BIOSIS  COPYRIGHT (c) 2007 The Thomson Corporation  on STN
AN   2004:327917  BIOSIS
DN   PREV200400325847
TI   Protein kinase G from pathogenic mycobacteria promotes survival
     within macrophages.
AU   Walburger, Anne; Koul, Anil; Ferrari, Giorgio; Nguyen, Liem;
     Prescianotto-Baschong, Cristina; Huygen, Kris; Klebl, Bert; Thompson,
     Charles; Bacher, Gerald; Pieters, Jean [Reprint Author]
CS   Biozentrum, Univ Basel, Klingelbergstr 50-70, CH-4056, Basel, Switzerland
     jean.pieters@unibas.ch
SO   Science (Washington D C), (June 18 2004) Vol. 304, No. 5678, pp.
     1800-1804. print.
     ISSN: 0036-8075 (ISSN print).
DT   Article
LA   English
ED   Entered STN: 29 Jul 2004
     Last Updated on STN: 29 Jul 2004

L15  ANSWER 2 OF 7  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2004:722914  CAPLUS
DN   141:236625
TI   Inhibitors of mycobacterial serine/threonine protein kinases for
     the treatment of mycobacterial infections
IN   Pato, Janos; Keri, Gyorgy; Orfi, Laszlo; Waczek, Frigyes; Horvath, Zoltan;
     Banhegyi, Peter; Szabadkai, Istavan; Marosfalvi, Jeno; Hegymegi-Barakonyi,
     Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas, Axel; Bacher,
     Gerald; Missio, Andrea; Koul, Anil
PA   Hung.
SO   U.S. Pat. Appl. Publ., 51 pp., Cont.-in-part of Appl. No. PCT/EP03/03697.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 3
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ---------------     ----   --------    --------------------     --------
PI   US 2004171603        A1    20040902    US 2003-715591           20031118
     WO 2002094796        A2    20021128    WO 2002-EP5573           20020521
     WO 2002094796        A3    20031204
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
             GN, GQ, GW, ML, MR, NE, SN, TD, TG
     WO 2003084947        A1    20031016    WO 2003-EP3697           20030409
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI EP 2001-112289       A     20010518
```

	US 2001-292325P	P	20010522
	US 2001-298902P	P	20010619
	EP 2001-115508	A	20010627
	EP 2002-7923	A	20020409
	WO 2002-EP5573	A2	20020521
	WO 2003-EP3697	A2	20030409

OS MARPAT 141:236625

L15 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:483844 CAPLUS
DN 141:187540
TI Protein Kinase G from Pathogenic Mycobacteria Promotes Survival Within Macrophages
AU Walburger, Anne; Koul, Anil; Ferrari, Giorgio; Nguyen, Liem; Prescianotto-Baschong, Cristina; Huygen, Kris; Klebl, Bert; Thompson, Charles; Bacher, Gerald; Pieters, Jean
CS Biozentrum, University of Basel, Basel, CH-4056, Switz.
SO Science (Washington, DC, United States) (2004), 304(5678), 1800-1805
CODEN: SCIEAS; ISSN: 0036-8075
PB American Association for the Advancement of Science
DT Journal
LA English
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:818414 CAPLUS
DN 139:317414
TI 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections
IN Missio, Andrea; Bacher, Gerald; Koul, Anil; Choidas, Axel
PA Axxima Pharmaceuticals A.-G., Germany
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084947	A1	20031016	WO 2003-EP3697	20030409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003224054	A1	20031020	AU 2003-224054	20030409
	EP 1492783	A1	20050105	EP 2003-720441	20030409
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2004171603	A1	20040902	US 2003-715591	20031118
PRAI	EP 2002-7923	A	20020409		
	EP 2001-112289	A	20010518		
	US 2001-292325P	P	20010522		
	US 2001-298902P	P	20010619		
	EP 2001-115508	A	20010627		
	WO 2002-EP5573	A2	20020521		
	WO 2003-EP3697	W	20030409		

OS MARPAT 139:317414
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:906175 CAPLUS
DN 138:14074
TI Preparation of benzo[g]quinoxalines for use against infectious diseases
IN Pato, Janos; Keri, Gyoergy; Oerfi, Laszlo; Waczek, Frigyes; Horvath, Zoltan; Banhegyi, Peter; Szabadkai, Istvan; Marosfalvi, Jenoe; Hegymegi-barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas, Axel; Bacher, Gerald; Daub, Henrik; Obert, Sabine; Kurtenbach, Alexander; Habenberger, Peter
PA Axxima Pharmaceuticals Ag, Germany; et al.
SO PCT Int. Appl., 237 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002094796	A2	20021128	WO 2002-EP5573	20020521
	WO 2002094796	A3	20031204		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002312927	A1	20021203	AU 2002-312927	20020521
	US 2004171603	A1	20040902	US 2003-715591	20031118
PRAI	EP 2001-112289	A	20010518		
	US 2001-292325P	P	20010522		
	US 2001-298902P	P	20010619		
	EP 2001-115508	A	20010627		
	EP 2002-7923	A	20020409		
	WO 2002-EP5573	W	20020521		
	WO 2003-EP3697	A2	20030409		

OS MARPAT 138:14074

L15 ANSWER 6 OF 7 LIFESCI COPYRIGHT 2007 CSA on STN
AN 2004:66514 LIFESCI
TI Protein Kinase G from Pathogenic Mycobacteria Promotes Survival Within Macrophages
AU Walburger, Anne; Koul, Anil; Ferrari, Giorgio; Nguyen, Liem; Prescianotto-Baschong, Cristina; Huygen, Kris; Klebl, Bert; Thompson, Charles; Bacher, Gerald; Pieters, Jean
CS Biozentrum, University of Basel, Klingelbergstr. 50/70, CH-4056 Basel, Switzerland; E-mail: jean.pieters@unibas.ch
SO Science (Washington) [Science (Wash.)], (20040618) vol. 304, no. 5678, pp. 1800-1804.
ISSN: 0036-8075.
DT Journal
FS J; F
LA English
SL English

L15 ANSWER 7 OF 7 MEDLINE on STN
AN 2004303871 MEDLINE
DN PubMed ID: 15155913
TI Protein kinase G from pathogenic mycobacteria promotes survival within macrophages.

AU Walburger Anne; Koul Anil; Ferrari Giorgio; Nguyen Liem; Prescianotto-Baschong Cristina; Huygen Kris; Klebl Bert; Thompson Charles; Bacher Gerald; Pieters Jean
CS Biozentrum, University of Basel, Klingelbergstr. 50/70, CH-4056 Basel, Switzerland.
SO Science (New York, N.Y.), (2004 Jun 18) Vol. 304, No. 5678, pp. 1800-4. Electronic Publication: 2004-05-20. Journal code: 0404511. E-ISSN: 1095-9203.
CY United States
DT Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200407
ED Entered STN: 24 Jun 2004
Last Updated on STN: 21 Jul 2004
Entered Medline: 20 Jul 2004

=> e missio andrea/au
E1 7 MISSINOU MICHEL ANOUMOU/AU
E2 8 MISSIO A/AU
E3 34 --> MISSIO ANDREA/AU
E4 1 MISSIO C/AU
E5 1 MISSIO C A/AU
E6 1 MISSIO D V/AU
E7 1 MISSIO E/AU
E8 6 MISSIO E L/AU
E9 3 MISSIO EVANDRO LUIZ/AU
E10 1 MISSIO G/AU
E11 1 MISSIO L/AU
E12 1 MISSIO L J/AU

=> s e2-e4 and mycobacter?
L16 5 ("MISSIO A"/AU OR "MISSIO ANDREA"/AU OR "MISSIO C"/AU) AND MYCOBACTER?

=> d 1-
YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y

L16 ANSWER 1 OF 5 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2006:247378 BIOSIS
DN PREV200600248365
TI Inhibitors of a mycobacterial protein kinase target and their conversion into novel drug candidates for Mycobacterium tuberculosis infected patients.
AU Orfi, L. [Reprint Author]; Koul, A.; Hafenbradl, D.; Klebl, B.; Hoppe, E.; Missio, A.; Mueller, G.; Ullrich, A.; Pato, J.; Waczek, F.; Marko, P.; Banhegyi, P.; Greff, Z.; Keri, G.
CS Semmelweis Univ, Dept Pharmaceut Chem, Budapest, Hungary
lorfi@vichem.hu
SO FEBS Journal, (JUL 2005) Vol. 272, No. Suppl. 1, pp. 522. Meeting Info.: 30th Congress of the Federation-of-European-Biochemical-Societies (FEBS)/9th IUBMB Conference. Budapest, HUNGARY. July 02 -07, 2005. Federat European Biochem Soc; Int Union Biochem Mol Biol. ISSN: 1742-464X. E-ISSN: 1742-4658.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 26 Apr 2006
Last Updated on STN: 26 Apr 2006

L16 ANSWER 2 OF 5 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2005:415966 BIOSIS

DN PREV200510201557
TI Inhibitors of the mycobacterial kinase PknG provide completely new options for the treatment of tuberculosis.
AU Klebl, B. M. [Reprint Author]; Koul, A.; Missio, A.; Pieters, J.
SO Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, (OCT-NOV 2004) Vol. 44, pp. 226.
Meeting Info.: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA. October 30 -November 02, 2004.
ISSN: 0733-6373.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 19 Oct 2005
Last Updated on STN: 19 Oct 2005

L16 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:238994 CAPLUS
DN 142:316820
TI Preparation of hetero-bicyclic fused thieno-pyran compounds as antibacterial, antiviral, antitumor, and pharmaceutically active agents
IN Koul, Anil; Klebl, Bert; Mueller, Gerhard; Missio, Andrea; Schwab, Wilfried; Hafenbradl, Doris; Neumann, Lars; Sommer, Marc-Nicola; Mueller, Stefan; Hoppe, Edmund; Freisleben, Achim; Backes, Alexander; Hartung, Christian; Felber, Beatrice; Zech, Birgit; Engkvist, Ola; Keri, Gyoergy; Oerfi, Laszlo; Banhegyi, Peter; Greff, Zoltan; Horvath, Zoltan; Varga, Zoltan; Marko, Peter; Pato, Janos; Szabadkai, Istvan; Szekelyhidi, Zsolt; Waczek, Frigyes
PA Axxima Pharmaceuticals A.-G., Germany
SO PCT Int. Appl., 259 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005023818	A2	20050317	WO 2004-EP10161	20040910
	WO 2005023818	A3	20050825		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004270394	A1	20050317	AU 2004-270394	20040910
	CA 2572750	A1	20050317	CA 2004-2572750	20040910
	EP 1670804	A2	20060621	EP 2004-786934	20040910
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	EP 2003-20616	A	20030910		
	US 2003-502606P	P	20030915		
	EP 2004-4891	A	20040302		
	US 2004-551341P	P	20040310		
	EP 2004-12814	A	20040528		
	US 2004-577043P	P	20040607		
	WO 2004-EP10161	W	20040910		

OS MARPAT 142:316820

L16 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:722914 CAPLUS

DN 141:236625
TI Inhibitors of mycobacterial serine/threonine protein kinases for the treatment of mycobacterial infections
IN Pato, Janos; Keri, Gyorgy; Orfi, Laszlo; Waczek, Frigyes; Horvath, Zoltan; Banhegyi, Peter; Szabadkai, Istavan; Marosfalvi, Jeno; Hegymegi-Barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas, Axel; Bacher, Gerald; Missio, Andrea; Koul, Anil
PA Hung.
SO U.S. Pat. Appl. Publ., 51 pp., Cont.-in-part of Appl. No. PCT/EP03/03697.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004171603	A1	20040902	US 2003-715591	20031118
	WO 2002094796	A2	20021128	WO 2002-EP5573	20020521
	WO 2002094796	A3	20031204		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2003084947	A1	20031016	WO 2003-EP3697	20030409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	EP 2001-112289	A	20010518		
	US 2001-292325P	P	20010522		
	US 2001-298902P	P	20010619		
	EP 2001-115508	A	20010627		
	EP 2002-7923	A	20020409		
	WO 2002-EP5573	A2	20020521		
	WO 2003-EP3697	A2	20030409		

OS MARPAT 141:236625

L16 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:818414 CAPLUS
DN 139:317414
TI 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections
IN Missio, Andrea; Bacher, Gerald; Koul, Anil; Choidas, Axel
PA Axxima Pharmaceuticals A.-G., Germany
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084947	A1	20031016	WO 2003-EP3697	20030409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

```
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    AU 2003224054        A1    20031020    AU 2003-224054         20030409
    EP 1492783           A1    20050105    EP 2003-720441         20030409
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    US 2004171603        A1    20040902    US 2003-715591         20031118
PRAI EP 2002-7923        A     20020409
    EP 2001-112289       A     20010518
    US 2001-292325P      P     20010522
    US 2001-298902P      P     20010619
    EP 2001-115508       A     20010627
    WO 2002-EP5573       A2    20020521
    WO 2003-EP3697       W     20030409
OS  MARPAT 139:317414
RE.CNT  3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> e koul anil/au
E1            1     KOUL AJAY RAJ/AU
E2            1     KOUL AJAZ N/AU
E3           59 --> KOUL ANIL/AU
E4           13     KOUL ANJILA/AU
E5            8     KOUL ANJNI/AU
E6            3     KOUL ASHOK/AU
E7           26     KOUL ASHOK K/AU
E8            2     KOUL ASHOK KUMAR/AU
E9            1     KOUL ASHOK RAJ/AU
E10          30     KOUL ASHWANI/AU
E11           7     KOUL AWTAR K/AU
E12           1     KOUL AWTAR KRISHAN/AU

=> s e3 and mycobacter?
L17          52 "KOUL ANIL"/AU AND MYCOBACTER?

=> dup rem l17
PROCESSING COMPLETED FOR L17
L18          26 DUP REM L17 (26 DUPLICATES REMOVED)

=> d 1-
YOU HAVE REQUESTED DATA FROM 26 ANSWERS - CONTINUE? Y/(N):y

L18  ANSWER 1 OF 26  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2007:150833  CAPLUS
DN   146:229200
TI   Preparation of quinoline derivatives as antibacterial agents
IN   Guillemont, Jerome Emile Georges; Pasquier, Elisabeth Therese Jeanne;
     Lancois, David Francis Alain; Andries, Koenraad Jozef Lodewijk Marcel;
     Koul, Anil; Backx, Leo Jacobus Jozef; Meerpoel, Lieven
PA   Janssen Pharmaceutica N.V., Belg.
SO   PCT Int. Appl., 59pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007014941	A2	20070208	WO 2006-EP64858	20060731
	WO 2007014941	A3	20070329		
	WO 2007014941	A8	20070503		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

	BG 109179	A	20061229	BG 2005-109179	20050609
PRAI	EP 2005-107164	A	20050803		

OS MARPAT 146:229200

L18 ANSWER 2 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:150180 CAPLUS
DN 146:229198
TI Preparation of quinoline derivatives as antibacterial agents
IN Andries, Koenraad Jozef Lodewijk Marcel; Koul, Anil; Guillemont, Jerome Emile Georges; Pasquier, Elisabeth Therese Jeanne
PA Janssen Pharmaceutica N.V., Belg.
SO PCT Int. Appl., 63pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007014934	A2	20070208	WO 2006-EP64847	20060731
	WO 2007014934	A3	20070405		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRAI	EP 2005-107155	A	20050803		

OS MARPAT 146:229198

L18 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:143490 CAPLUS
DN 146:229195
TI Preparation of quinoline derivatives as antibacterial agents
IN Guillemont, Jerome Emile Georges; Lancois, David Francis Alain; Pasquier, Elisabeth Therese Jeanne; Andries, Koenraad Jozef Lodewijk Marcel; Koul, Anil
PA Janssen Pharmaceutica N.V., Belg.
SO PCT Int. Appl., 109pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007014885	A1	20070208	WO 2006-EP64656	20060726

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI EP 2005-106962 A 20050728
OS MARPAT 146:229195
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:10962 CAPLUS
DN 146:121844
TI Quinoline derivatives as antibacterial agents and their preparation, pharmaceutical compositions and use in the treatment of bacterial infections
IN Andries, Koenraad Jozef Lodewijk Marcel; Koul, Anil; Guillemont, Jerome Emile Georges; Motte, Magali Madeleine Simone
PA Janssen Pharmaceutica N.V., Belg.
SO PCT Int. Appl., 88pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007000436	A1	20070104	WO 2006-EP63556	20060626

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI EP 2005-105769 A 20050628
OS MARPAT 146:121844
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:14921 CAPLUS
DN 146:121847
TI Quinoline derivatives as antibacterial agents and their preparation, pharmaceutical compositions and use in the treatment of bacterial infections
IN Andries, Koenraad Jozef Lodewijk Marcel; Koul, Anil; Guillemont, Jerome Emile Georges; Lancois, David Francis Alain; Motte, Magali Madeleine Simone; Dorange, Ismet; Backx, Leo Jacobus Jozef; Meerpoel, Lieven

PA Janssen Pharmaceutica N.V., Belg.
SO PCT Int. Appl., 118pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007000435	A1	20070104	WO 2006-EP63553	20060626

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI EP 2005-105762 A 20050628
OS MARPAT 146:121847
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:13533 CAPLUS
DN 146:121846
TI Quinoline derivatives as antibacterial agents and their preparation, pharmaceutical compositions and use in the treatment of bacterial infections
IN Andries, Koenraad Jozef Lodewijk Marcel; Koul, Anil; Lancois, David Francis Alain; Motte, Magali Madeleine Simone; Guillemont, Jerome Emile Georges
PA Janssen Pharmaceutica N.V., Belg.
SO PCT Int. Appl., 62pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007000434	A1	20070104	WO 2006-EP63552	20060626

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI EP 2005-105755 A 20050628
OS MARPAT 146:121846
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 7 OF 26 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
DUPLICATE 1
AN 2007:389150 BIOSIS

DN PREV200700389779
TI A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910.
AU de Jonge, Marc R. [Reprint Author]; Koymans, Luc H. H.; Guillemont, Jerome E. G.; Koul, Anil; Andries, Koen
CS BVBA, Molmo Serv, Campus Blairon 424, B-2300 Turnhout, Belgium
marc@molmo.be
SO Proteins Structure Function and Bioinformatics, (JUN 2007) Vol. 67, No. 4, pp. 971-980.
CODEN: PSFGEY. ISSN: 0887-3585.
DT Article
LA English
ED Entered STN: 11 Jul 2007
Last Updated on STN: 11 Jul 2007

L18 ANSWER 8 OF 26 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
DUPLICATE 2
AN 2007:431369 BIOSIS
DN PREV200700438829
TI Diarylquinolines target subunit c of mycobacterial ATP synthase.
AU Koul, Anil [Reprint Author]; Dendouga, Najoua; Vergauwen, Karen; Molenberghs, Brenda; Vranckx, Luc; Willebrords, Rudy; Ristic, Zorica; Lill, Holger; Dorange, Ismet; Guillemont, Jerome; Bald, Dirk; Andries, Koen
CS Tibotec BVBA, Dept Antimicrobial Res, Turnhoutseweg 30, B-2340 Beerse, Belgium
akoul@prdbe.jnj.com
SO Nature Chemical Biology, (JUN 2007) Vol. 3, No. 6, pp. 323-324.
ISSN: 1552-4450. E-ISSN: 1552-4469.
DT Article
Editorial
LA English
ED Entered STN: 15 Aug 2007
Last Updated on STN: 15 Aug 2007

L18 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:714185 CAPLUS
DN 147:134382
TI Novel quinoline derivative for treating bacterial infection except mycobacteria infection
IN Andries, Koenraad Jozef Lodewijk Marcel; Koul, Anil; Guillemont, Jerome Emile Georges; Pasquier, Elisabeth Therese Jeanne
PA Janssen Pharmaceutica N.V., Belg.
SO Repub. Korean Kongkae Taeho Kongbo, No pp. given
CODEN: KRXXA7
DT Patent
LA Korean
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	KR 2006128191	A	20061214	KR 2005-49427	20050609
PRAI	KR 2005-49427		20050609		

L18 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:626680 CAPLUS
DN 145:103574
TI Preparation of quinoline derivatives and their use as mycobacterial inhibitors
IN Koul, Anil; Andries, Koenraad Jozef Lodewijk Marcel
PA Janssen Pharmaceutica N.V., Belg.
SO Can. Pat. Appl., 62 pp.
CODEN: CPXXEB
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2529265	A1	20060624	CA 2005-2529265	20051206
	BG 109180	A	20060630	BG 2005-109180	20050609
	JP 2006182755	A	20060713	JP 2005-170052	20050609
	EE 200500033	A	20060815	EE 2005-33	20051205
	AU 2005242138	A1	20060713	AU 2005-242138	20051207
	US 2006142279	A1	20060629	US 2005-296992	20051208
	WO 2006067048	A1	20060629	WO 2005-EP56594	20051208
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	BR 2005006400	A	20060829	BR 2005-6400	20051208
	MX 2005PA13413	A	20061110	MX 2005-PA13413	20051208
	LV 13469	B	20070120	LV 2005-161	20051209
PRAI	EP 2004-78529	A	20041224		
	EP 2005-105008	A	20050608		
OS	MARPAT 145:103574				

L18 ANSWER 11 OF 26 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN DUPLICATE 3

AN 2006:383083 BIOSIS

DN PREV200600381078

TI Transcriptional control of the mycobacterial embCAB operon by PknH through a regulatory protein, EmbR, in vivo.

AU Sharma, Kirti; Gupta, Meetu; Pathak, Monika; Gupta, Nidhi; Koul, Anil; Sarangi, Smilona; Baweja, Renu; Singh, Yogendra [Reprint Author]

CS IGIB, Mall Rd, Delhi 110007, India
ysingh@igib.res.in

SO Journal of Bacteriology, (APR 2006) Vol. 188, No. 8, pp. 2936-2944.
CODEN: JOBAAY. ISSN: 0021-9193.

DT Article

LA English

ED Entered STN: 2 Aug 2006
Last Updated on STN: 2 Aug 2006

L18 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:238994 CAPLUS

DN 142:316820

TI Preparation of hetero-bicyclic fused thieno-pyran compounds as antibacterial, antiviral, antitumor, and pharmaceutically active agents

IN Koul, Anil; Klebl, Bert; Mueller, Gerhard; Missio, Andrea; Schwab, Wilfried; Hafenbradl, Doris; Neumann, Lars; Sommer, Marc-Nicola; Mueller, Stefan; Hoppe, Edmund; Freisleben, Achim; Backes, Alexander; Hartung, Christian; Felber, Beatrice; Zech, Birgit; Engkvist, Ola; Keri, Gyoergy; Oerfi, Laszlo; Banhegyi, Peter; Greff, Zoltan; Horvath, Zoltan; Varga, Zoltan; Marko, Peter; Pato, Janos; Szabadkai, Istvan; Szekelyhidi, Zsolt; Waczek, Frigyes

PA Axxima Pharmaceuticals A.-G., Germany

SO PCT Int. Appl., 259 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005023818	A2	20050317	WO 2004-EP10161	20040910
	WO 2005023818	A3	20050825		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004270394	A1	20050317	AU 2004-270394	20040910
	CA 2572750	A1	20050317	CA 2004-2572750	20040910
	EP 1670804	A2	20060621	EP 2004-786934	20040910
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	EP 2003-20616	A	20030910		
	US 2003-502606P	P	20030915		
	EP 2004-4891	A	20040302		
	US 2004-551341P	P	20040310		
	EP 2004-12814	A	20040528		
	US 2004-577043P	P	20040607		
	WO 2004-EP10161	W	20040910		

OS MARPAT 142:316820

L18 ANSWER 13 OF 26 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2006:24942 BIOSIS
DN PREV200600021917
TI Role of protein kinase G in growth and glutamine metabolism of Mycobacterium bovis BCG (vol 187, pg 5852, 2005).
AU Nguyen, Liem [Reprint Author]; Walburger, Anne; Houben, Edith; Koul, Anil; Muller, Stefan; Morbitzer, Monika; Klebl, Bert; Ferrari, Giorgio; Pieters, Jean
CS Univ Basel, Biozentrum, Basel, Switzerland
SO Journal of Bacteriology, (OCT 2005) Vol. 187, No. 20, pp. 7165.
CODEN: JOBAAY. ISSN: 0021-9193.
DT Article
Errata
LA English
ED Entered STN: 21 Dec 2005
Last Updated on STN: 21 Dec 2005

L18 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1124743 CAPLUS
DN 144:146235
TI Role of protein kinase G in growth and glutamine metabolism of Mycobacterium bovis BCG. [Erratum to document cited in CA143:321955]
AU Nguyen, Liem; Walburger, Anne; Houben, Edith; Koul, Anil; Muller, Stefan; Morbitzer, Monika; Klebl, Bert; Ferrari, Giorgio; Pieters, Jean
CS Biozentrum, University of Basel, Basel, Switz.
SO Journal of Bacteriology (2005), 187(20), 7165
CODEN: JOBAAY; ISSN: 0021-9193
PB American Society for Microbiology
DT Journal
LA English

L18 ANSWER 15 OF 26 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN DUPLICATE 4

AN 2005:491313 BIOSIS

DN PREV200510280156

TI Role of protein kinase G in growth and glutamine metabolism of Mycobacterium bovis BCG.

AU Nguyen, Liem; Walburger, Anne; Houben, Edith; Koul, Anil; Muller, Stefan; Morbitzer, Monika; Klebl, Bert; Ferrari, Giorgio; Pieters, Jean [Reprint Author]

CS Univ Basel, Biozentrum, Klingelbergstr 50, CH-4056 Basel, Switzerland jean.pieters@unibas.ch

SO Journal of Bacteriology, (AUG 2005) Vol. 187, No. 16, pp. 5852-5856. CODEN: JOBAAY. ISSN: 0021-9193.

DT Article

LA English

ED Entered STN: 16 Nov 2005
Last Updated on STN: 16 Nov 2005

L18 ANSWER 16 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:722914 CAPLUS

DN 141:236625

TI Inhibitors of mycobacterial serine/threonine protein kinases for the treatment of mycobacterial infections

IN Pato, Janos; Keri, Gyorgy; Orfi, Laszlo; Waczek, Frigyes; Horvath, Zoltan; Banhegyi, Peter; Szabadkai, Istavan; Marosfalvi, Jeno; Hegymegi-Barakonyi, Balint; Szekelyhidi, Zsolt; Greff, Zoltan; Choidas, Axel; Bacher, Gerald; Missio, Andrea; Koul, Anil

PA Hung.

SO U.S. Pat. Appl. Publ., 51 pp., Cont.-in-part of Appl. No. PCT/EP03/03697. CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004171603	A1	20040902	US 2003-715591	20031118
	WO 2002094796	A2	20021128	WO 2002-EP5573	20020521
	WO 2002094796	A3	20031204		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2003084947	A1	20031016	WO 2003-EP3697	20030409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	EP 2001-112289	A	20010518		
	US 2001-292325P	P	20010522		
	US 2001-298902P	P	20010619		
	EP 2001-115508	A	20010627		
	EP 2002-7923	A	20020409		

WO 2002-EP5573 A2 20020521
WO 2003-EP3697 A2 20030409
OS MARPAT 141:236625

L18 ANSWER 17 OF 26 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN DUPLICATE 5
AN 2004:327917 BIOSIS
DN PREV200400325847
TI Protein kinase G from pathogenic mycobacteria promotes survival within macrophages.
AU Walburger, Anne; Koul, Anil; Ferrari, Giorgio; Nguyen, Liem; Prescianotto-Baschong, Cristina; Huygen, Kris; Klebl, Bert; Thompson, Charles; Bacher, Gerald; Pieters, Jean [Reprint Author]
CS Biozentrum, Univ Basel, Klingelbergstr 50-70, CH-4056, Basel, Switzerland jean.pieters@unibas.ch
SO Science (Washington D C), (June 18 2004) Vol. 304, No. 5678, pp. 1800-1804. print.
ISSN: 0036-8075 (ISSN print).
DT Article
LA English
ED Entered STN: 29 Jul 2004
Last Updated on STN: 29 Jul 2004

L18 ANSWER 18 OF 26 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN DUPLICATE 6
AN 2004:404277 BIOSIS
DN PREV200400402826
TI Nucleoside diphosphate kinase as GTPase-activating FEBS 28622 of Mycobacterium tuberculosis acts protein for Rho-GTPases.
AU Chopra, Puneet; Koduri, Harshavardhan; Singh, Ramandeep; Koul, Anil; Ghildiyal, Megha; Sharma, Kirti; Tyagi, Anil K.; Singh, Yogendra [Reprint Author]
CS Inst Genom and Integrat Biol, Mall Rd, Delhi, India ysingh@igib.res.in
SO FEBS Letters, (July 30 2004) Vol. 571, No. 1-3, pp. 212-216. print.
CODEN: FEBLAL. ISSN: 0014-5793.
DT Article
LA English
ED Entered STN: 20 Oct 2004
Last Updated on STN: 20 Oct 2004

L18 ANSWER 19 OF 26 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN DUPLICATE 7
AN 2004:464275 BIOSIS
DN PREV200400462713
TI Interplay between mycobacteria and host signalling pathways.
AU Koul, Anil [Reprint Author]; Herget, Thomas; Klebl, Bert; Ullrich, Axel
CS Axxima Pharmaceut AG, Max Lebsche Pl 32, D-81377, Munich, Germany anil.koul@axxima.com
SO Nature Reviews Microbiology, (March 2004) Vol. 2, No. 3, pp. 189-202. print.
ISSN: 1740-1526 (ISSN print).
DT Article
General Review; (Literature Review)
LA English
ED Entered STN: 1 Dec 2004
Last Updated on STN: 1 Dec 2004

L18 ANSWER 20 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:818414 CAPLUS
DN 139:317414
TI 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections

IN Missio, Andrea; Bacher, Gerald; Koul, Anil; Choidas, Axel
PA Axxima Pharmaceuticals A.-G., Germany
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084947	A1	20031016	WO 2003-EP3697	20030409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003224054	A1	20031020	AU 2003-224054	20030409
	EP 1492783	A1	20050105	EP 2003-720441	20030409
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2004171603	A1	20040902	US 2003-715591	20031118
PRAI	EP 2002-7923	A	20020409		
	EP 2001-112289	A	20010518		
	US 2001-292325P	P	20010522		
	US 2001-298902P	P	20010619		
	EP 2001-115508	A	20010627		
	WO 2002-EP5573	A2	20020521		
	WO 2003-EP3697	W	20030409		

OS MARPAT 139:317414
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 21 OF 26 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN DUPLICATE 8
AN 2003:562194 BIOSIS
DN PREV200300550858
TI Disruption of mptpB impairs the ability of Mycobacterium tuberculosis to survive in guinea pigs.
AU Singh, Ramandeep; Rao, Vivek; Shakila, H.; Gupta, Radhika; Khera, Aparna; Dhar, Neeraj; Singh, Amit; Koul, Anil; Singh, Yogendra; Naseema, M.; Narayanan, P. R.; Paramasivan, C. N.; Ramanathan, V. D.; Tyagi, Anil K. [Reprint Author]
CS Department of Biochemistry, University of Delhi South campus, Benito Juarez Road, New Delhi, 110021, India
akt1000@hotmail.com
SO Molecular Microbiology, (November 2003) Vol. 50, No. 3, pp. 751-762. print.
ISSN: 0950-382X (ISSN print).
DT Article
LA English
ED Entered STN: 26 Nov 2003
Last Updated on STN: 26 Nov 2003

L18 ANSWER 22 OF 26 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN DUPLICATE 9
AN 2003:179722 BIOSIS
DN PREV200300179722
TI Cytotoxic activity of nucleoside diphosphate kinase secreted from Mycobacterium tuberculosis.
AU Chopra, Puneet; Singh, Anubha; Koul, Anil; Ramachandran, S.;

Drlica, Karl; Tyagi, Anil K.; Singh, Yogendra [Reprint Author]
CS Institute of Genomics and Integrative Biology, Mall Road, Near Jubilee Hall, Delhi, 110 007, India
ysingh@cbt.res.in
SO European Journal of Biochemistry, (February 2003) Vol. 270, No. 4, pp. 625-634. print.
ISSN: 0014-2956 (ISSN print).
DT Article
LA English
ED Entered STN: 9 Apr 2003
Last Updated on STN: 9 Apr 2003

L18 ANSWER 23 OF 26 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN DUPLICATE 10
AN 2004:26875 BIOSIS
DN PREV200400028047
TI Phosphoprotein phosphatase of Mycobacterium tuberculosis dephosphorylates serine-threonine kinases PknA and PknB.
AU Chopra, Puneet; Singh, Bhuminder; Singh, Ramandeep; Vohra, Reena; Koul, Anil; Meena, Laxman S.; Koduri, Harshavardhan; Ghildiyal, Megha; Deol, Parampal; Das, Taposh K.; Tyagi, Anil K.; Singh, Yogendra [Reprint Author]
CS Institute of Genomics and Integrative Biology, Mall Road, Delhi, India
ysingh@igib.res.in; ysingh30@hotmail.com
SO Biochemical and Biophysical Research Communications, (November 7 2003) Vol. 311, No. 1, pp. 112-120. print.
CODEN: BBRCA9. ISSN: 0006-291X.
DT Article
LA English
ED Entered STN: 31 Dec 2003
Last Updated on STN: 31 Dec 2003

L18 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:798298 CAPLUS
DN 135:356745
TI Inhibition of secretory tyrosine phosphatases from Mycobacterium tuberculosis
IN Ullrich, Axel; Koul, Anil
PA Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Germany
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001081422	A1	20011101	WO 2001-EP4463	20010419
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1274732	A1	20030115	EP 2001-945021	20010419
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003180304	A1	20030925	US 2003-257935	20030324
PRAI	EP 2000-108682	A	20000420		
	WO 2001-EP4463	W	20010419		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 25 OF 26 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN DUPLICATE 11
AN 2001:440206 BIOSIS
DN PREV200100440206
TI Serine/threonine protein kinases PknF and PknG of Mycobacterium tuberculosis: Characterization and localization.
AU Koul, Anil; Choidas, Axel; Tyagi, Anil K.; Drlica, Karl; Singh, Yogendra [Reprint author]; Ullrich, Axel
CS Centre for Biochemical Technology, Mall Road, Delhi, 110 007, India ysingh@cbt.res.in
SO Microbiology (Reading), (August, 2001) Vol. 147, No. 8, pp. 2307-2314. print.
ISSN: 1350-0872.
DT Article
LA English
ED Entered STN: 19 Sep 2001
Last Updated on STN: 22 Feb 2002

L18 ANSWER 26 OF 26 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN DUPLICATE 12
AN 2000:439757 BIOSIS
DN PREV200000439757
TI Cloning and characterization of secretory tyrosine phosphatases of Mycobacterium tuberculosis.
AU Koul, Anil; Choidas, Axel; Treder, Martin; Tyagi, Anil K.; Drlica, Karl; Singh, Yogendra; Ullrich, Axel [Reprint author]
CS Department of Molecular Biology, Max-Planck-Institut fuer Biochemie, Am Klopferspitz 18A, 82152, Martinsried, Germany
SO Journal of Bacteriology, (October, 2000) Vol. 182, No. 19, pp. 5425-5432. print.
CODEN: JOBAAY. ISSN: 0021-9193.
DT Article
LA English
ED Entered STN: 18 Oct 2000
Last Updated on STN: 10 Jan 2002

=> s mycobacter? and 2(cyclopropanecarbonyl-amino)-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carbosylic acid amide
MISSING OPERATOR 'AND 2(CYCLOPROPA'
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s mycobacter? and (2(cyclopropanecarbonyl-amino)-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carbosylic acid amide)
MISSING OPERATOR '(2(CYCLOPROPA'
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s mycobacter? and (2cyclopropanecarbonyl-amino-4,5,6,7-tetrahydro-benzo-b-thiophene-3-carbosylic acid amide)
L19 0 MYCOBACTER? AND (2CYCLOPROPANECARBONYL-AMINO-4,5,6,7-TETRAHYDRO-BENZO-B-THIOPHENE-3-CARBOSYLIC ACID AMIDE)

=> s mycobacter? and (benzoquinoxaline derivativ?)
L20 0 MYCOBACTER? AND (BENZOQUINOXALINE DERIVATIV?)

=> s mycobacter? and (?quinoxaline derivativ?)
LEFT TRUNCATION IGNORED FOR FILE 'LIFESCI'
L21 23 MYCOBACTER? AND (?QUINOXALINE DERIVATIV?)

Left truncation is not valid in the specified search field in the specified file. The term has been searched without left truncation. Examples: '?TERPEN?' would be searched as 'TERPEN?' and '?FLAVONOID' would be searched as 'FLAVONOID.'

If you are searching in a field that uses implied proximity, and you used a truncation symbol after a punctuation mark, the system may interpret the truncation symbol as being at the beginning of a term. Implied proximity is used in search fields indexed as single words, for example, the Basic Index.

```
=> dup rem l21
PROCESSING COMPLETED FOR L21
L22          15 DUP REM L21 (8 DUPLICATES REMOVED)

=> d bib ab kwic 1-
YOU HAVE REQUESTED DATA FROM 15 ANSWERS - CONTINUE? Y/(N):y

L22  ANSWER 1 OF 15  BIOSIS  COPYRIGHT (c) 2007 The Thomson Corporation  on STN
     DUPLICATE 1
AN   2003:68236  BIOSIS
DN   PREV200300068236
TI   Synthesis and antimycobacterial activity of pyrazine and
     quinoxaline derivatives.
AU   Seitz, Lainne E.; Suling, William J.; Reynolds, Robert C. [Reprint Author]
CS   Organic Chemistry Department, Southern Research Institute, P.O. Box 55305,
     Birmingham, AL, 35255-5305, USA
     reynolds@sri.org
SO   Journal of Medicinal Chemistry, (December 5 2002) Vol. 45, No. 25, pp.
     5604-5606. print.
     ISSN: 0022-2623 (ISSN print).
DT   Article
LA   English
ED   Entered STN: 29 Jan 2003
     Last Updated on STN: 29 Jan 2003
AB   A series of pyrazine and quinoxaline derivatives have
     been synthesized, and their activity against M. tuberculosis (Mtb) and
     Mycobacterium avium (MAC) are reported.  The 4-acetoxybenzyl ester
     of pyrazinoic acid and 4'-acetoxybenzyl 2-quinoxalinecarboxylate showed
     excellent activity against Mtb (MIC ranges of less than 1-6.25 mug/mL) but
     only modest activity against MAC (MICs of 4-32 mug/mL).
TI   Synthesis and antimycobacterial activity of pyrazine and
     quinoxaline derivatives.
AB   A series of pyrazine and quinoxaline derivatives have
     been synthesized, and their activity against M. tuberculosis (Mtb) and
     Mycobacterium avium (MAC) are reported.  The 4-acetoxybenzyl ester
     of pyrazinoic acid and 4'-acetoxybenzyl 2-quinoxalinecarboxylate showed
     excellent activity against Mtb (MIC ranges.  .  .
ORGN Classifier
          Mycobacteriaceae   08881
     Super Taxa
          Mycobacteria; Actinomycetes and Related Organisms;
       Eubacteria; Bacteria; Microorganisms
     Organism Name
          Mycobacterium avium (species): pathogen
          Mycobacterium tuberculosis (species): pathogen
     Taxa Notes
        Bacteria, Eubacteria, Microorganisms

L22  ANSWER 2 OF 15  BIOSIS  COPYRIGHT (c) 2007 The Thomson Corporation  on STN
     DUPLICATE 2
AN   2002:232356  BIOSIS
DN   PREV200200232356
TI   Anti-Mycobacterium tuberculosis agents derived from
```

quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-di-N-oxide.
AU Ortega, Miguel Angel; Sainz, Yolanda; Montoya, Maria Elena; Jaso, Andres; Zarranz, Belen; Aldana, Ignacio; Monge, Antonio [Reprint author]
CS Centro de Investigacion en Farmacobiologia Apliacada, Universidad de Navarra, 31080, Pamplona, Spain
amonge@unav.es
SO Arzneimittel-Forschung, (2002) Vol. 52, No. 2, pp. 113-119. print.
CODEN: ARZNAD. ISSN: 0004-4172.
DT Article
LA English
ED Entered STN: 3 Apr 2002
Last Updated on STN: 10 May 2002
AB In this paper new quinoxaline derivatives with different substituents in positions 3, 6, 7 and 8 are reported. Their biological activities against Mycobacterium tuberculosis have been assessed and most of the 1,4-di-N-oxide derivatives have been shown to strongly inhibit the bacteria growth in the first in vitro screening. One of these N-oxides (4) is a promising candidate due to its good Selectivity Index (7.95). On the other hand, those compounds without N-oxide moieties showed no or very low activity (growth inhibition: 17% and 39%).
TI Anti-Mycobacterium tuberculosis agents derived from quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-di-N-oxide.
AB In this paper new quinoxaline derivatives with different substituents in positions 3, 6, 7 and 8 are reported. Their biological activities against Mycobacterium tuberculosis have been assessed and most of the 1,4-di-N-oxide derivatives have been shown to strongly inhibit the bacteria growth in. . .
ORGN Classifier
Mycobacteriaceae 08881
Super Taxa
Mycobacteria; Actinomycetes and Related Organisms; Eubacteria; Bacteria; Microorganisms
Organism Name
Mycobacterium tuberculosis
Taxa Notes
Bacteria, Eubacteria, Microorganisms

L22 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:202178 CAPLUS
TI Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives
AU Seitz, Lainne E.; Suling, William J.; Reynolds, Robert C.
CS Division of Organic Chemistry, Southern Research Institute, Birmingham, AL, 35255-5305, USA
SO Abstracts of Papers, 221st ACS National Meeting, San Diego, CA, United States, April 1-5, 2001 (2001) MEDI-273
CODEN: 69FZD4
PB American Chemical Society
DT Journal; Meeting Abstract
LA English
AB Mycobacterium tuberculosis (TB) is estimated to infect approx. one third of the world's population and kills over 2 million people annually. There is a critical need for new, more effective antitubercular agents. Pyrazinamide (PZA) is commonly used in combination with other drugs as a treatment of tuberculosis. In our research program for the discovery and development of antitubercular drugs, a series of pyrazine and quinoxaline derivs. were synthesized and their mycobacterial activity against Mycobacterium tuberculosis and Mycobacterium avium (MAC) were evaluated. Certain analogs showed excellent activity with MIC values < 6.25 μg/mL. The synthesis and antimycobacterial activity of these compds. will be presented.
TI Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives

AB Mycobacterium tuberculosis (TB) is estimated to infect approx. one third of the world's population and kills over 2 million people annually. There is a critical need for new, more effective antitubercular agents. Pyrazinamide (PZA) is commonly used in combination with other drugs as a treatment of tuberculosis. In our research program for the discovery and development of antitubercular drugs, a series of pyrazine and quinoxaline derivs. were synthesized and their mycobacterial activity against Mycobacterium tuberculosis and Mycobacterium avium (MAC) were evaluated. Certain analogs showed excellent activity with MIC values < 6.25 μg/mL. The synthesis and antimycobacterial activity of these compds. will be presented.

L22 ANSWER 4 OF 15 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 2001:297251 BIOSIS
DN PREV200100297251
TI Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives.
AU Seitz, Lainne E. [Reprint author]; Suling, William J.; Reynolds, Robert C. [Reprint author]
CS Division of Organic Chemistry, Southern Research Institute, Birmingham, AL, 35255-5305, USA
seitz@sri.org
SO Abstracts of Papers American Chemical Society, (2001) Vol. 221, No. 1-2, pp. MEDI 273. print.
Meeting Info.: 221st National Meeting of the American Chemical Society. San Diego, California, USA. April 01-05, 2001. American Chemical Society.
CODEN: ACSRAL. ISSN: 0065-7727.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 20 Jun 2001
Last Updated on STN: 19 Feb 2002
TI Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives.
IT Major Concepts
Infection; Pharmacology
IT Diseases
tuberculosis: bacterial disease
Tuberculosis (MeSH)
IT Chemicals & Biochemicals
pyrazine derivatives; quinoxaline derivatives
ORGN Classifier
Mycobacteriaceae 08881
Super Taxa
Mycobacteria; Actinomycetes and Related Organisms; Eubacteria; Bacteria; Microorganisms
Organism Name
Mycobacterium avium
Mycobacterium tuberculosis
Taxa Notes
Bacteria, Eubacteria, Microorganisms

L22 ANSWER 5 OF 15 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
DUPLICATE 3
AN 2001:158943 BIOSIS
DN PREV200100158943
TI Quinoxaline derivatives as potential antituberculotic agents.
AU Kunes, J. [Reprint author]; Spulak, M.; Waisser, K.; Slosarek, M.; Janota, J.
CS Department of Inorganic and Organic Chemistry, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 50005, Hradec Kralove, Czech Republic
kunes@faf.cuni.cz

SO Pharmazie, (November, 2000) Vol. 55, No. 11, pp. 858-859. print.
CODEN: PHARAT. ISSN: 0031-7144.
DT Article
LA English
ED Entered STN: 28 Mar 2001
Last Updated on STN: 15 Feb 2002
TI Quinoxaline derivatives as potential antituberculotic agents.
IT Major Concepts
Pharmacology
IT Chemicals & Biochemicals
quinoxaline derivatives: activity, antituberculotic agent, structure, synthesis
ORGN Classifier
Mycobacteriaceae 08881
Super Taxa
Mycobacteria; Actinomycetes and Related Organisms; Eubacteria; Bacteria; Microorganisms
Organism Name
Mycobacterium avium
Mycobacterium fortuitum
Mycobacterium intracellulare
Mycobacterium kansasii
Mycobacterium tuberculosis
Taxa Notes
Bacteria, Eubacteria, Microorganisms

L22 ANSWER 6 OF 15 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
DUPLICATE 4
AN 1997:511870 BIOSIS
DN PREV199799811073
TI Antimycobacterial activity of some 2,3-dianilinoquinoxaline derivatives.
AU Waisser, K. [Reprint author]; Beckert, R.; Slosafrek, M.; Janota, J.
CS Heyrovsky-Str. 1203, CZ 50005 Hradec Kralove, Czech Republic
SO Pharmazie, (1997) Vol. 52, No. 10, pp. 797-798.
CODEN: PHARAT. ISSN: 0031-7144.
DT Article
LA English
ED Entered STN: 10 Dec 1997
Last Updated on STN: 10 Dec 1997
AB The antimycobacterial activity of 2,3-dianilinoquinoxaline derivatives was studied and the substances were found to be mostly wide-spectrum antimycobacterial agents. Replacement of one nitrogen atom in the heterocycle for oxygen or sulfur was usually accompanied by loss of activity. The model structure for the study was the wide-spectrum antimycobacterial drug clofazimine.
TI Antimycobacterial activity of some 2,3-dianilinoquinoxaline derivatives.
AB The antimycobacterial activity of 2,3-dianilinoquinoxaline derivatives was studied and the substances were found to be mostly wide-spectrum antimycobacterial agents. Replacement of one nitrogen atom in the. . .
IT Miscellaneous Descriptors
ANTIBACTERIAL-DRUG; ANTIBIOTICS; ANTIMYCOBACTERIAL ACTIVITY; BACTERIAL DISEASE; BIOBUSINESS; CLOFAZIMINE; MOLECULAR STRUCTURES; PHARMACOLOGY; TUBERCULOSIS; 2,3-DIANILINOQUINOXALINE DERIVATIVES
ORGN . . .
Taxa Notes
Bacteria, Eubacteria, Microorganisms
ORGN Classifier
Microorganisms 01000
Super Taxa
Microorganisms

Organism Name
microorganism
Taxa Notes
Microorganisms
ORGN Classifier
Mycobacteriaceae 08881
Super Taxa
Mycobacteria; Actinomycetes and Related Organisms;
Eubacteria; Bacteria; Microorganisms
Organism Name
Mycobacterium spp.
Taxa Notes
Bacteria, Eubacteria, Microorganisms

L22 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1997:672543 CAPLUS
DN 127:328824
TI Antimycobacterial activity of some 2,3-dianilinoquinoxaline derivatives with substituents in position 6
AU Waisser, K.; Beckert, R.; Slosarek, M.; Janota, J.
CS Faculty Pharmacy, Charles University, Hradec Kralove, 50005, Czech Rep.
SO Scientia Pharmaceutica (1997), 65(3), 109-112
CODEN: SCPHA4; ISSN: 0036-8709
PB Oesterreichische Apotheker-Verlagsgesellschaft
DT Journal
LA English
AB The 2,3-dianilinoderivatives can be considered to be potential antimycobacterial substances with a wide spectrum of effects. The present paper investigated the effect of a substituent in position 6 of 2,3-dianilinoquinoxaline on the antimicrobial activity against Mycobacterium tuberculosis, M. kansasii, M. fortuitum, M. avium, and M. intracellulare. The electron-donor activities of a substituent in the above mentioned position increase the activity, on the other hand the presence of the electron-acceptor substituents (nitrogroups, benzoyl) results in a strong decrease or even a loss of activity. Replacement one or 2 of the N atoms in quinoxaline for S also results in a decrease or even a loss of activity.
TI Antimycobacterial activity of some 2,3-dianilinoquinoxaline derivatives with substituents in position 6
AB The 2,3-dianilinoderivatives can be considered to be potential antimycobacterial substances with a wide spectrum of effects. The present paper investigated the effect of a substituent in position 6 of 2,3-dianilinoquinoxaline on the antimicrobial activity against Mycobacterium tuberculosis, M. kansasii, M. fortuitum, M. avium, and M. intracellulare. The electron-donor activities of a substituent in the above mentioned position increase the activity, on the other hand the presence of the electron-acceptor substituents (nitrogroups, benzoyl) results in a strong decrease or even a loss of activity. Replacement one or 2 of the N atoms in quinoxaline for S also results in a decrease or even a loss of activity.
ST dianilinoquinoxaline deriv Mycobacterium antibacterial tuberculostatic
IT Antibacterial agents
Mycobacterium avium
Mycobacterium fortuitum
Mycobacterium intracellulare
Mycobacterium kansasii
Mycobacterium tuberculosis
Tuberculostatics
(antimycobacterial activity of some 2,3-dianilinoquinoxaline derivs. with substituents in position 6)

L22 ANSWER 8 OF 15 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
DUPLICATE 5

AN 1995:388699 BIOSIS
DN PREV199598402999
TI Synthesis of some quinoxaline derivatives containing indoline-2,3-dione or thiazolidinone residue as potential antimicrobial agents.
AU El-Gendy, Adel A. [Reprint author]; El-Meligie, Salwa; El-Ansary, Afaf K.; Ahmedy, Aly M.
CS Organic Chem. Dep., Fac. Pharm., Cairo Univ., 11562 Cairo, Egypt
SO Archives of Pharmacal Research (Seoul), (1995) Vol. 18, No. 1, pp. 44-47. CODEN: APHRDQ. ISSN: 0253-6269.
DT Article
LA English
ED Entered STN: 13 Sep 1995
Last Updated on STN: 10 Oct 1995
AB The synthesis of some quinoxaline derivatives containing indoline-2,3-dione or thiazolidinone residue is described. The synthesized derivatives were screened in vitro for their growth inhibitory activity against six species of bacteria, viz. Staphylococcus aureus, Streptococcus faecalis, Escherichia coli, Pseudomonas aeruginosa, Serratia marcescens and Mycobacterium smegmatis. Most of the compounds exhibited antimicrobial activity especially those having indoline-2,3-dione moiety.
TI Synthesis of some quinoxaline derivatives containing indoline-2,3-dione or thiazolidinone residue as potential antimicrobial agents.
AB The synthesis of some quinoxaline derivatives containing indoline-2,3-dione or thiazolidinone residue is described. The synthesized derivatives were screened in vitro for their growth inhibitory activity against six species of bacteria, viz. Staphylococcus aureus, Streptococcus faecalis, Escherichia coli, Pseudomonas aeruginosa, Serratia marcescens and Mycobacterium smegmatis. Most of the compounds exhibited antimicrobial activity especially those having indoline-2,3-dione moiety.
ORGN . . .
Micrococcaceae 07702
Super Taxa
Gram-Positive Cocci; Eubacteria; Bacteria; Microorganisms
Organism Name
Staphylococcus aureus
Taxa Notes
Bacteria, Eubacteria, Microorganisms
ORGN Classifier
Mycobacteriaceae 08881
Super Taxa
Mycobacteria; Actinomycetes and Related Organisms; Eubacteria; Bacteria; Microorganisms
Organism Name
Mycobacterium smegmatis
Taxa Notes
Bacteria, Eubacteria, Microorganisms
ORGN Classifier
Pseudomonadaceae 06508
Super Taxa
Gram-Negative Aerobic Rods and Cocci; Eubacteria; Bacteria; Microorganisms

L22 ANSWER 9 OF 15 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
AN 1984:329036 BIOSIS
DN PREV198478065516; BA78:65516
TI BROMINE ANALOGS OF QUINOXIDINE DIOXIDINE AND DI N OXIDES OF 3 HYDROXYMETHYL QUINOXALINE-2-CARBOXYLIC-ACID AMIDES.
AU MUSATOVA I S [Reprint author]; ELINA A S; SOLOV'EVA N P; POLUKHINA L M; MOSKALENKO N YU; PERSHIN G N
CS S ORDZHONIKIDZE ALL-UNION RES CHEM-PHARM INST, MOSCOW, USSR

SO Khimiko-Farmatsevticheskii Zhurnal, (1983) Vol. 17, No. 11, pp. 1307-1312.
CODEN: KHFZAN. ISSN: 0023-1134.
DT Article
FS BA
LA RUSSIAN
AB Bromine analogs of the biologically active quinoxaline derivatives were synthesized in order to study their antimicrobial activity. The activity was tested in vitro with respect to 4 gram-positive bacterial spp., 5 gram-negative bacterial spp., 3 mycobacterial spp. and 5 pathogenic fungus spp. The majority of the compounds possessed an expressed activity with respect to gram-positive and acid-resistant mycobacteria. 2-Carbetoxy-3-methyl-7-bromoquinoxaline di-N-oxide had a broad spectrum of activity, as did the compounds C11H10BrN3O4 and C12H12BrN3O5. All compounds possessed sufficiently pronounced antituberculosis activity. C11H10BrN3O4, C13H12BrN3O4 and C18H16BrN3O4 were the most effective compounds with respect to Mycobacterium tuberculosis strain H37Rv.
AB Bromine analogs of the biologically active quinoxaline derivatives were synthesized in order to study their antimicrobial activity. The activity was tested in vitro with respect to 4 gram-positive bacterial spp., 5 gram-negative bacterial spp., 3 mycobacterial spp. and 5 pathogenic fungus spp. The majority of the compounds possessed an expressed activity with respect to gram-positive and acid-resistant mycobacteria. 2-Carbetoxy-3-methyl-7-bromoquinoxaline di-N-oxide had a broad spectrum of activity, as did the compounds C11H10BrN3O4 and C12H12BrN3O5. All compounds possessed sufficiently pronounced antituberculosis activity. C11H10BrN3O4, C13H12BrN3O4 and C18H16BrN3O4 were the most effective compounds with respect to Mycobacterium tuberculosis strain H37Rv.
IT Miscellaneous Descriptors
MYCOBACTERIUM-TUBERCULOSIS BACTERIA FUNGUS 2 CARBETOXY-3-METHYL-7-BROMO QUINOXALINE DI-N OXIDE ANTIBACTERIAL-DRUG ANTIFUNGAL-DRUG/
ORGN Classifier
Bacteria 05000
Super Taxa
Microorganisms
Taxa Notes
Bacteria, Eubacteria, Microorganisms
ORGN Classifier
Mycobacteriaceae 08881
Super Taxa
Mycobacteria; Actinomycetes and Related Organisms; Eubacteria; Bacteria; Microorganisms
Taxa Notes
Bacteria, Eubacteria, Microorganisms
ORGN Classifier
Fungi 15000
Super Taxa
Plantae
Taxa. . .

L22 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1979:6351 CAPLUS
DN 90:6351
TI Studies in quinoxaline series. Part X. Synthesis of 2-methyl-3-oxo-3,4-dihydroquinoxaline derivatives
AU Toman, Jaromir; Klicnar, Jiri; Machacek, Vladimir
CS Org. Chem. Dep., Inst. Chem. Technol., Pardubice, Czech.
SO Collection of Czechoslovak Chemical Communications (1978), 43(8), 2179-89
CODEN: CCCCAK; ISSN: 0366-547X
DT Journal

LA English
OS CASREACT 90:6351
AB I (R1, R2, R3, R4 = H, Me, Cl, NO2, MeO) were prepared by reaction of MeCOCH2CO2Et with 3-oxo-3,4-dihydroquinoxaline 1-oxides obtained by cyclization of 2'-nitroacetoacetanilides or from 1,2-diaminobenzenes and EtO2CCH2COCO2Et or EtO2CC.tplbond.CCO2Et. II (R = H, Me, Ph; R1 = H, NO2) were prepared from 1,2-diaminobenzenes and EtO2CCOCHRCN. Several N-Me derivs. of I (R1-4 = H) and III (R = CO2Et, CN, NO2; R1 = Cl, OH, Me, MeO) were prepared Out of 7 tested compds., I (R1 = R3 = NO2, R2 = R4 = H) is the most active against Staphylococcus pyogenes aureus, Mycobacterium tbc. H37Rv, Trichophyton mentagrophytes and Saccharomyces pasterianus.
TI Studies in quinoxaline series. Part X. Synthesis of 2-methyl-3-oxo-3,4-dihydroquinoxaline derivatives
AB I (R1, R2, R3, R4 = H, Me, Cl, NO2, MeO) were prepared by reaction of MeCOCH2CO2Et with 3-oxo-3,4-dihydroquinoxaline 1-oxides obtained by cyclization of 2'-nitroacetoacetanilides or from 1,2-diaminobenzenes and EtO2CCH2COCO2Et or EtO2CC.tplbond.CCO2Et. II (R = H, Me, Ph; R1 = H, NO2) were prepared from 1,2-diaminobenzenes and EtO2CCOCHRCN. Several N-Me derivs. of I (R1-4 = H) and III (R = CO2Et, CN, NO2; R1 = Cl, OH, Me, MeO) were prepared Out of 7 tested compds., I (R1 = R3 = NO2, R2 = R4 = H) is the most active against Staphylococcus pyogenes aureus, Mycobacterium tbc. H37Rv, Trichophyton mentagrophytes and Saccharomyces pasterianus.

L22 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1960:34350 CAPLUS
DN 54:34350
OREF 54:6769f-h
TI Quinoxaline derivatives
IN Asano, Kazuo; Asai, Sotoo; Inoue, Naoyuki
PA Dai-ichi Industrial Drug Manufg. Co.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 34008524	B4	19590922	JP	

AB To a suspension of 50 g. 2,3-dimercaptoquinoxaline in 1 l. H2O is added 16 g. 80% aqueous solution N2H4.H2O, heated 1 hr. at 100°, and filtered to give 31.4 g. 2-mercapto-3-hydrazinoquinoxaline (I), m. 254° (decomposition) (70% aqueous solution of dioxane). Antibacterial activity of I in vitro is as follows (bacteria and min. growth inhibition concentration are): Mycobacterium tuberculosis, 0.78; Escherichia coli, 1.56; Pseudomonas aeruginosa, 12.5; Salmonella paratyphi, 0.78; S. typhosa, 3.12; Shigella dysenteriae, 0.39-0.78; Vibrio comma, 0.78; Staphylococcus aureus, 3.12; S. albus, 3.12; Streptococcus J17A4, 0.78; Bacillus agri, 0.78; B. subtilis, 0.78; Sartina lutea, 6.25; Candida albicans, 6.25; C. tropicalis, 6.25; C. paracrusei, 1.56; Aspergillus niger, 6.25; A. oryzae, 6.25; A. fumigus, 3.12; A. glaucus, 6.25. The following N-3-(2-mercapto)quinoxalyl-N'-R-substituted hydrazines are prepared from I (R, appearance, and m.p. (decomposition) given): glucosyl, yellow needles, 183-4°; glucuronoyl, yellow microneedles, 202-5°; acetyl, yellow microneedles, above 300°; pyruvoyl, yellow powder, 245°. These derivs. are H2O-soluble
TI Quinoxaline derivatives
AB To a suspension of 50 g. 2,3-dimercaptoquinoxaline in 1 l. H2O is added 16 g. 80% aqueous solution N2H4.H2O, heated 1 hr. at 100°, and filtered to give 31.4 g. 2-mercapto-3-hydrazinoquinoxaline (I), m. 254° (decomposition) (70% aqueous solution of dioxane). Antibacterial activity of I in vitro is as follows (bacteria and min. growth inhibition concentration are): Mycobacterium tuberculosis, 0.78; Escherichia coli, 1.56;

Pseudomonas aeruginosa, 12.5; Salmonella paratyphi, 0.78; S. typhosa, 3.12; Shigella dysenteriae, 0.39-0.78; Vibrio comma, 0.78; Staphylococcus aureus, 3.12; S. albus, 3.12; Streptococcus J17A4, 0.78; Bacillus agri, 0.78; B. subtilis, 0.78; Sartina lutea, 6.25; Candida albicans, 6.25; C. tropicalis, 6.25; C. paracrusei, 1.56; Aspergillus niger, 6.25; A. oryzae, 6.25; A. fumigus, 3.12; A. glaucus, 6.25. The following N-3-(2-mercapto)quinoxalyl-N'-R-substituted hydrazines are prepared from I (R, appearance, and m.p. (decomposition) given): glucosyl, yellow needles, 183-4°; glucuronoyl, yellow microneedles, 202-5°; acetyl, yellow microneedles, above 300°; pyruvoyl, yellow powder, 245°. These derivs. are H2O-soluble

L22 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1959:122219 CAPLUS
DN 53:122219
OREF 53:21979f-i
TI Chemotherapeutics. VII. Syntheses of hydrazinoquinoxaline derivatives. 2
AU Asano, Kazuo; Asai, Sotoo
CS Daiichi Pharm. Co., Takatsuki, Osaka-fu
SO Yakugaku Zasshi (1959), 79, 661-3
CODEN: YKKZAJ; ISSN: 0031-6903
DT Journal
LA Unavailable
AB 2-Mercaptoquinoxaline (I) (0.5 g.) in 5 ml. EtOH and 0.16 g. 80% N2H4.H2O (II) refluxed 1 hr. and the solution cooled gave 0.3 g. 2-hydrazinoquinoxaline, needles, m. 167° (decomposition). 2,3-Dichloroquinoxaline (1 g.) in 15 ml. 8.7% MeSH-C6H6 and 0.25 g. Na heated 13 hrs. at 50-60° and the product recrystd. (EtOH) gave 2-methylthio-3-chloroquinoxaline (III), needles, m. 102-3°. III (0.5 g.) in 10 ml. 5% KOH absorbed 1 g. H2S; the product heated 10 hrs. and the solution acidified gave 2-methylthio-3-mercaptoquinoxaline (IV), needles, m. 227° (EtOH). IV (0.2 g.) in 3 ml. EtOH and 0.5 ml. II refluxed 1 hr. gave 0.14 g. 2-methylthio-3-hydrazinoquinoxaline (V), needles, m. 157° (MeOH). 2-Mercapto-3-hydrazinoquinoxaline (VI) (1 g.) in 20 ml. C5H5N and 0.3 g. Ac2O or 0.41 g. AcCl refluxed 1 hr. and the C5H5N removed gave 0.7 g. 3-AcNHNH analog (VII) of VI, m. above 300° (EtOH). VII could be prepared also by refluxing 1 g. VI and 0.8 g. 1-acetyl-3,5-dimethylpyrazole in EtOH. VI (1 g.) and 1.1 g. 1-isonicotinoyl-3,5-dimethylpyrazole (VIII) in 15 ml. EtOH treated as above gave 2-mercapto-3-isonicotinoylhydrazinoquinoxaline, needles, m. above 300° (C5H5N). Similarly, 1.5 g. VI and 1.3 g. 3-ClCOC5H4N gave 2-mercapto-3-nicotinoylhydrazinoquinoxaline, m. above 300°. VII (0.5 g.) in 20 ml. EtOH and 2N HCl heated 15 min. on a H2O bath and the product filtered off gave 0.4 g. 1-methyl-4-mercapto-1,2,4-triazolo[4,3-a]quinoxaline in needles. 2-Hydroxy-3-hydrazinoquinoxaline (IX) (0.5 g.) and 0.5 g. 1-acetyl-3,5-dimethylpyrazole in 10 ml. EtOH refluxed 6 hrs. gave the 3-AcNHNH derivative of IX, needles, m. above 300°. IX (0.5 g.) and 0.6 g. VIII yielded 0.6 g. 2-hydroxy-3-isonicotinoylhydrazinoquinoxaline, m. above 300°. None of these compds. showed higher antibacterial action than VI which inhibited the growth of Mycobacterium tuberculosis H 37 Rv. at the dilution of 1.56 γ/ml.
TI Chemotherapeutics. VII. Syntheses of hydrazinoquinoxaline derivatives. 2
AB 2-Mercaptoquinoxaline (I) (0.5 g.) in 5 ml. EtOH and 0.16 g. 80% N2H4.H2O (II) refluxed 1 hr. and the solution cooled gave 0.3 g. 2-hydrazinoquinoxaline, needles, m. 167° (decomposition). 2,3-Dichloroquinoxaline (1 g.) in 15 ml. 8.7% MeSH-C6H6 and 0.25 g. Na heated 13 hrs. at 50-60° and the product recrystd. (EtOH) gave 2-methylthio-3-chloroquinoxaline (III), needles, m. 102-3°. III (0.5 g.) in 10 ml. 5% KOH absorbed 1 g. H2S; the product heated 10 hrs. and the solution acidified gave 2-methylthio-3-mercaptoquinoxaline (IV), needles, m. 227° (EtOH). IV (0.2 g.) in 3 ml. EtOH and 0.5 ml. II

refluxed 1 hr. gave 0.14 g. 2-methylthio-3-hydrazinoquinoxaline (V), needles, m. 157° (MeOH). 2-Mercapto-3-hydrazinoquinoxaline (VI) (1 g.) in 20 ml. C5H5N and 0.3 g. Ac2O or 0.41 g. AcCl refluxed 1 hr. and the C5H5N removed gave 0.7 g. 3-AcNHNH analog (VII) of VI, m. above 300° (EtOH). VII could be prepared also by refluxing 1 g. VI and 0.8 g. 1-acetyl-3,5-dimethylpyrazole in EtOH. VI (1 g.) and 1.1 g. 1-isonicotinoyl-3,5-dimethylpyrazole (VIII) in 15 ml. EtOH treated as above gave 2-mercapto-3-isonicotinoylhydrazinoquinoxaline, needles, m. above 300° (C5H5N). Similarly, 1.5 g. VI and 1.3 g. 3-ClCOC5H4N gave 2-mercapto-3-nicotinoylhydrazinoquinoxaline, m. above 300°. VII (0.5 g.) in 20 ml. EtOH and 2N HCl heated 15 min. on a H2O bath and the product filtered off gave 0.4 g. 1-methyl-4-mercapto-1,2,4-triazolo[4,3-a]quinoxaline in needles. 2-Hydroxy-3-hydrazinoquinoxaline (IX) (0.5 g.) and 0.5 g. 1-acetyl-3,5-dimethylpyrazole in 10 ml. EtOH refluxed 6 hrs. gave the 3-AcNHNH derivative of IX, needles, m. above 300°. IX (0.5 g.) and 0.6 g. VIII yielded 0.6 g. 2-hydroxy-3-isonicotinoylhydrazinoquinoxaline, m. above 300°. None of these compds. showed higher antibacterial action than VI which inhibited the growth of Mycobacterium tuberculosis H 37 Rv. at the dilution of 1.56 γ/ml.

L22 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1959:73915 CAPLUS
DN 53:73915
OREF 53:13401b-f
TI Chemotherapeutics. IV. Antibacterial action of 2-mercapto-3-hydrazinoquinoxaline derivatives on various bacteria
AU Asano, Kazuo; Asai, Satoo; Inoue, Naoyuki
CS Daiichi Seiyaku Co., Osaka-fu
SO Yakugaku Zasshi (1959), 79, 368-70
CODEN: YKKZAJ; ISSN: 0031-6903
DT Journal
LA Unavailable
AB cf. C.A. 53, 10242d. 2-Mercapto-3-hydrazinoquinoxaline (I) (0.5 g.) and 0.7 g. glucuronolactone in 15 ml. 50% AcOH were dissolved by heating, kept overnight, and the product filtered off to give 0.69 g. product; this in a small amount of H2O heated for 30 min. on a water bath and cooled gave glucuronic acid 2-mercapto-3-quinoxalinylhydrazone, m. 185° (decomposition); this in MeOH refluxed for 3 hrs. and cooled gave glucuronolactone 2-mercapto-3-quinoxalinylhydrazone, m. 213° (decomposition). Similarly were prepared other 3-NHN:R analogs of I (R, m.p. and min. inhibitory concentration in γ/ml. for Mycobacterium tuberculosis H37Rv given): O.CH:CH.CH:CCH:, 244° (decomposition), 12.5; O.CH:CH.CH:CCMe:, 271° (decomposition), 12.5; glucosyl, 184° (decomposition), 6.25; arabinosyl, 137° (decomposition), 6.25; rhamnosyl, 205° (decomposition), 25; HO2CCMe:, 245° (decomposition), 25; EtO2CCMe:, 239°, -; HO2C[Me(CH2)8]C:, 218° (decomposition), 50; HO2C[Me(CH2)16]C:, 209° (decomposition), 50; EtO2CCH2CMe:, 189°, 6.25; EtO2CCHMeCMe:, 202°, 6.25; EtO2CCHPrCMe:, 229°, 12.5; EtO2CCHBuCMe: 236°, 12.5. I (1 g.) in 10.5 ml. N KOH and 0.89 g. MeNHNH2.H2SO4 in 4 ml. EtOH refluxed 10 hrs. gave 0.5 g. 3-RNHNH analog (II) of I (R = Me). Similarly were prepared other II (R, m.p. (decomposition), and min. inhibitory concentration in γ/ml. for M. tuberculosis given): Me, 220°, 12.5; Ph, 217°, 25; p-MeC6H4, 212°, 50; p-ClC6H4, 216°, 50. None of them showed stronger activity than I.
TI Chemotherapeutics. IV. Antibacterial action of 2-mercapto-3-hydrazinoquinoxaline derivatives on various bacteria
AB cf. C.A. 53, 10242d. 2-Mercapto-3-hydrazinoquinoxaline (I) (0.5 g.) and 0.7 g. glucuronolactone in 15 ml. 50% AcOH were dissolved by heating, kept overnight, and the product filtered off to give 0.69 g. product; this in a small amount of H2O heated for 30 min. on a water bath and cooled gave glucuronic acid 2-mercapto-3-quinoxalinylhydrazone, m. 185° (decomposition); this in MeOH refluxed for 3 hrs. and cooled gave

glucuronolactone 2-mercapto-3-quinoxalinylhydrazone, m. 213° (decomposition). Similarly were prepared other 3-NHN:R analogs of I (R, m.p. and min. inhibitory concentration in γ/ml. for Mycobacterium tuberculosis H37Rv given): O.CH:CH.CH:CCH:, 244° (decomposition), 12.5; O.CH:CH.CH:CCMe:, 271° (decomposition), 12.5; glucosyl, 184° (decomposition), 6.25; arabinosyl, 137° (decomposition), 6.25; rhamnosyl, 205° (decomposition), 25; HO2CCMe:, 245° (decomposition), 25; EtO2CCMe:, 239°, -; HO2C[Me(CH2)8]C:, 218° (decomposition), 50; HO2C[Me(CH2)16]C:, 209° (decomposition), 50; EtO2CCH2CMe:, 189°, 6.25; EtO2CCHMeCMe:, 202°, 6.25; EtO2CCHPrCMe:, 229°, 12.5; EtO2CCHBuCMe: 236°, 12.5. I (1 g.) in 10.5 ml. N KOH and 0.89 g. MeNHNH2.H2SO4 in 4 ml. EtOH refluxed 10 hrs. gave 0.5 g. 3-RNHNH analog (II) of I (R = Me). Similarly were prepared other II (R, m.p. (decomposition), and min. inhibitory concentration in γ/ml. for M. tuberculosis given): Me, 220°, 12.5; Ph, 217°, 25; p-MeC6H4, 212°, 50; p-ClC6H4, 216°, 50. None of them showed stronger activity than I.

IT Mycobacterium tuberculosis
(3-hydrazino-2-quinoxalinethiol derivative effect on)

L22 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1959:56480 CAPLUS
DN 53:56480
OREF 53:10242d-g
TI Chemotherapeutics. III. Antibacterial activity of some quinoxaline derivatives on various bacteria
AU Asano, Kazuo; Asai, Satoo; Inoue, Naoyuki
CS Daiichi Pharm. Co., Takatsuki
SO Yakugaku Zasshi (1959), 79, 24-8
CODEN: YKKZAJ; ISSN: 0031-6903
DT Journal
LA Unavailable
AB cf. C.A. 52, 18428b. 2,3-Dimercaptoquinoxaline (50 g.) and 16 g. 80% N2H4.H2O heated 2 hrs. at 100°, cooled and the product recrystd. (EtOH) gave 2-mercapto-3-hydrazinoquinoxaline (I α-form), plates, m. 254° (decomposition); this in HCl was neutralized with NH4OH to give I (β-form), unmelted at 300°. I and an equivalent amount of an aldehyde or ketone in EtOH refluxed, cooled, the precipitate filtered off, washed with dilute HCl and recrystd. (MeOH or EtOH) gave the following 2-mercapto-3-quinoxalinylhydrazones (II) (ketone or aldehyde, m.p. (decomposition) of hydrazone, and the min. inhibitory concentration, γ/ml., for Mycobacterium tuberculosis given): Me2CO, 270°, 3.13; MeCOEt, 257°, 3.13; MeCOPr, 234°, 6.25; MeCOBu-iso, 263°, 3.13; MeCOAm, 231°, 3.13; MeCOAm-iso, 233°, 3.13; diacetone alc., 211°, 12.5; cyclohexanone, 248°, 3.13; Et2CO, 245°, 6.25; Pr2CO, 234°, 6.25; PhCOMe, 246°, 25; p-H2NC6H4COMe, 274°, 12.5; PhCH:CHCOMe, 258°, 25; AmCOPh, 218°, -; AcH, 236°, -; EtCHO, 211°, 6.25; BzH, 256°, 6.25; ogr;-HOC6H4CHO, 273°, 50; m-HOC6H4CHO, 263°, 3.13; p-HOC6H4CHO, 270°, 6.25; vanillin, 259°, 6.25; p-ClC6H4CHO, 271°, 12.5; PhCH:CHCHO, 238°, 25. II was also effective on gram pos. and neg. bacteria as in M. tuberculosis.

TI Chemotherapeutics. III. Antibacterial activity of some quinoxaline derivatives on various bacteria
AB cf. C.A. 52, 18428b. 2,3-Dimercaptoquinoxaline (50 g.) and 16 g. 80% N2H4.H2O heated 2 hrs. at 100°, cooled and the product recrystd. (EtOH) gave 2-mercapto-3-hydrazinoquinoxaline (I α-form), plates, m. 254° (decomposition); this in HCl was neutralized with NH4OH to give I (β-form), unmelted at 300°. I and an equivalent amount of an aldehyde or ketone in EtOH refluxed, cooled, the precipitate filtered off, washed with dilute HCl and recrystd. (MeOH or EtOH) gave the following

2-mercapto-3-quinoxalinylhydrazones (II) (ketone or aldehyde, m.p. (decomposition) of hydrazone, and the min. inhibitory concentration, γ/ml., for Mycobacterium tuberculosis given): Me2CO, 270°, 3.13; MeCOEt, 257°, 3.13; MeCOPr, 234°, 6.25; MeCOBu-iso, 263°, 3.13; MeCOAm, 231°, 3.13; MeCOAm-iso, 233°, 3.13; diacetone alc., 211°, 12.5; cyclohexanone, 248°, 3.13; Et2CO, 245°, 6.25; Pr2CO, 234°, 6.25; PhCOMe, 246°, 25; p-H2NC6H4COMe, 274°, 12.5; PhCH:CHCOMe, 258°, 25; AmCOPh, 218°, -; AcH, 236°, -; EtCHO, 211°, 6.25; BzH, 256°, 6.25; ogr;-HOC6H4CHO, 273°, 50; m-HOC6H4CHO, 263°, 3.13; p-HOC6H4CHO, 270°, 6.25; vanillin, 259°, 6.25; p-ClC6H4CHO, 271°, 12.5; PhCH:CHCHO, 238°, 25. II was also effective on gram pos. and neg. bacteria as in M. tuberculosis.

L22 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1958:104330 CAPLUS
DN 52:104330
OREF 52:18428g-i,18429a
TI Chemotherapeutics. II. Antituberculous activity of some quinoxaline derivatives
AU Asano, Kazuo
CS Daiichi Seiyaku Co., Akutagawa, Takatsuki
SO Yakugaku Zasshi (1958), 78, 729-33
CODEN: YKKZAJ; ISSN: 0031-6903
DT Journal
LA Unavailable
AB 2,3-R,R1-Disubstituted quinoxalines (I) (all new compds.) were prepared I (R, R1, m.p., and min. growth inhibitory concentration for Mycobacterium tuberculosis in γ/mL. given): CH:NNHCSNH2, H, 246° (decomposition), 12.5; 2-HOC6H4N:CH, H, 231° (decomposition), 3.13; CONH2, H, 191°, above 50; CONHNH2, H, 212°, 25; CONHNH2, NHNH2, 200° (decomposition), above 50; Cl, Pr, 73°, 25; Cl, n-C11H23, 57°, 25; Cl, n-C13H27, 62°, 25; Cl, n-C17H35, 73°, 25; NHNH2, H, 167° (decomposition), above 50; NHNH2, NHNH2, above 300°, 50; NHN:CMeCO2H, H, 225° (decomposition), 50; NHNH2, Me, 172° (decomposition), 50; NHNH2, Am, 137° (decomposition), 50; NHNH2, n-C11H23, 101°, 50; NHNH2, n-C13H27, 102°, 50; NHNH2, n-C17H35 103°, above 50; HO, n-C7H15, 140°, above 50; HO, n-C8H17, 122°, above 50; HO, n-C9H19, 128°, above 50; HO, n-C11H23, 126°, above 50; HO, n-C13H27, 123°, above 50; HO, nC17H35, 124°, above 50; HO, CH:CHCO2H, 175° (decomposition), 50; HO, CONHNH2, 334° (decomposition), 25; SH, SH, above 300°, 3.13; SH, Me, 254° (decomposition), 25; SH, n-C5H11, 173°, 50; SH, n-C11H23, 140°, 50; SH, n-C13H27, 136°, 50; SH, n-C17H35, 131°, 50; SH, Pr, 198°, above 50. The min. inhibitory concentration of 24 known compds. of I are also tabulated. The min. inhibitory concentration (γ/mL.) of the controls were as follows: p-H2NC6H4OH, 1.56; 4-C5H4NCONHNH2, 0.08; tibione, 12.5; streptomycin, 1.56; 2,4-HO(H2N)C6H3CO2H, 0.63.
TI Chemotherapeutics. II. Antituberculous activity of some quinoxaline derivatives
AB 2,3-R,R1-Disubstituted quinoxalines (I) (all new compds.) were prepared I (R, R1, m.p., and min. growth inhibitory concentration for Mycobacterium tuberculosis in γ/mL. given): CH:NNHCSNH2, H, 246° (decomposition), 12.5; 2-HOC6H4N:CH, H, 231° (decomposition), 3.13; CONH2, H, 191°, above 50; CONHNH2, H, 212°, 25; CONHNH2, NHNH2, 200° (decomposition), above 50; Cl, Pr, 73°, 25; Cl, n-C11H23, 57°, 25; Cl, n-C13H27, 62°, 25; Cl, n-C17H35, 73°, 25; NHNH2, H, 167° (decomposition), above 50; NHNH2, NHNH2, above 300°, 50; NHN:CMeCO2H, H, 225° (decomposition), 50; NHNH2, Me, 172° (decomposition), 50; NHNH2, Am, 137° (decomposition), 50; NHNH2, n-C11H23, 101°, 50; NHNH2, n-C13H27, 102°, 50; NHNH2, n-C17H35 103°, above 50; HO, n-C7H15, 140°, above 50; HO,

n-C8H17, 122°, above 50; HO, n-C9H19, 128°, above 50; HO, n-C11H23, 126°, above 50; HO, n-C13H27, 123°, above 50; HO, nC17H35, 124°, above 50; HO, CH:CHCO2H, 175° (decomposition), 50; HO, CONHNH2, 334° (decomposition), 25; SH, SH, above 300°, 3.13; SH, Me, 254° (decomposition), 25; SH, n-C5H11, 173°, 50; SH, n-C11H23, 140°, 50; SH, n-C13H27, 136°, 50; SH, n-C17H35, 131°, 50; SH, Pr, 198°, above 50. The min. inhibitory concentration of 24 known compds. of I are also tabulated. The min. inhibitory concentration (γ/mL.) of the controls were as follows: p-H2NC6H4OH, 1.56; 4-C5H4NCONHNH2, 0.08; tibione, 12.5; streptomycin, 1.56; 2,4-HO(H2N)C6H3CO2H, 0.63.